<!DOCTYPE html>
<html class="no-js" lang="en">
<head>
  <meta charset="utf-8" />
  <meta http-equiv="x-ua-compatible" content="ie=edge" />
  <title>
    PharmCAT Report [example]
  </title>

  <meta name="viewport" content="width=device-width, initial-scale=1" />

  <!-- HTML5 shim and Respond.js for IE8 support of HTML5 elements and media queries -->
  <!-- WARNING: Respond.js doesn't work if you view the page via file:// -->
  <!--[if lt IE 9]>
  <script src="https://oss.maxcdn.com/html5shiv/3.7.2/html5shiv.min.js"></script>
  <script src="https://oss.maxcdn.com/respond/1.4.2/respond.min.js"></script>
  <![endif]-->
  <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/font-awesome/4.7.0/css/font-awesome.min.css">
  <style>
    html {
      font-size: 16px;
    }
    body {
      font-weight: 300;
      -moz-osx-font-smoothing: grayscale;
      -webkit-font-smoothing: antialiased;
      line-height: 1.5;
      font-size: 1rem;
      font-family: "Museo Sans W01 Rounded",Arial,Helvetica,sans-serif;
      color: rgb(25, 31, 42);
      background-color: #FEFEFE;
      margin: 0 auto;
      max-width: 70em;
      padding: 1em 1em;
    }
    header {
      overflow: auto;
      margin-bottom: 1em;
    }
    h1, h2, h3, h4 {
      margin-top: 0.5rem;
      margin-bottom: 0.5rem;
    }
    a, h1, h2, h3, h4, h5, h6 {
      color: #3e4c6c;
    }
    h1 {
      font-size: 2em;
      font-weight: 100;
    }
    h2, h3, h4 {
      font-weight: 300;
    }
    h2 {
      font-size: 1.8em;
    }
    h3 {
      font-size: 1.5em;
    }
    h4 {
      font-size: 1.2em;
    }
    p {
      margin-top: 0;
      margin-bottom: 1em;
    }
    section {
      margin-bottom: 2.5rem;
    }
    table, ul {
      margin-bottom: 1.5rem;
    }
    table {
      min-width: 100%;
      border-collapse: collapse;
      border-color: grey;
      font-size: 0.9rem;
    }
    td, th {
      border: 1px solid rgba(62, 76, 108, 0.1);
      max-width: 600px;
      word-wrap: break-word;
      padding: 1em 1.3em;
    }
    th {
      text-align: left;
    }
    .table-small th {
      font-weight: normal;
      font-style: italic;
      width: 8em;
    }
    .table-small th, .table-small td {
      padding:.2em;
      font-size: .8em;
      border: 0;
    }

    hr {
      margin-bottom: 2em;
    }
    section.gene, section.guideline {
      margin-bottom: 4em;
      border-top: 1px solid #DDD;
    }

    .alert {
      margin: 1em 0;
      padding: 0.6em;
      border-radius: 4px;
      text-shadow: 0 1px 0 rgba(255, 255, 255, 0.5);
    }
    .alert-info {
      background-color: #d9edf7;
      border-color: #bce8f1;
      color: #3a87ad;
    }
    .alert-warning {
      background-color: #fcf8e3;
      border-color: #faebcc;
      color: #8a6d3b;
    }
    .alert-danger {
      background-color: #EAD6D5;
      border-color: #EFDFDE;
      color: #7C3A37;
    }
    .alert-danger h4 {
      color: #7C3A37;
      font-weight: bold;
    }

    .drugName {
      white-space: nowrap;
    }

    .drugName a:link, .drugName a:visited {
      color: darkgreen;
    }

    .normal {
      color: darkgreen;
    }

    .rxChange a:link, .rxChange a:visited {
      color: darkred;
    }

    .rxChange {
      color: darkred;
    }

    .rxPossibly a:link, .rxPossibly a:visited {
      color: darkorange;
    }

    .rxPossibly {
      color: darkorange;
    }

    .highlightDrug a:link, .highlightDrug a:visited {
      color: #3a87ad;
    }

    .highlight {
      color: #3a87ad;
    }

    td.missingVariant {
      background-color: lightsalmon;
    }

    .geneCall {
      font-size: 1.2em;
    }

    .footnote {
      padding: .5em 3em;
      font-style: italic;
      font-size: .8em;
    }

    #liability {
      font-size: 1.2em;
      color: darkred;
    }

    .image {
      text-align: center;
    }
    .image img {
      width: 80%;
      height: auto;
    }

    .nonwild {
      font-weight: bold;
    }

    @media print {
      html {
        font-size: 8px;
      }

      a {
        text-decoration: none;
      }

      img, pre, blockquote, table, figure, p {
        page-break-inside: avoid;
      }
    }
  </style>


</head>

<body>

<!--[if lt IE 9]>
<p class="browserupgrade">You are using an <strong>outdated</strong> browser. Please <a href="http://browsehappy.com/">upgrade your browser</a> to improve your experience.</p>
<![endif]-->

<h1>PharmCAT Report</h1>

<table class="table-small">
  <tr><th>Title</th><td>example</td></tr>
  <tr><th>Date created</th><td>April 26, 2018</td></tr>
  <tr><th>Version</th><td>v0.3.0-16-g455b909
</td></tr>
</table>

<div class="alert alert-danger">
  <h4>Pre-release software - For code testing only</h4>
  This software has not been officially released. You should only be using this software to evaluate whether the PharmCAT
  executable will compile and run properly on your system. The content of the reporting is not yet complete so <strong>results
  will change</strong>. The user recognizes they are using PharmCAT at their own risk.
</div>

<div class="alert alert-info">
  <em>Disclaimer:</em> The PharmCAT report is only able to generate recommendations based on the information imported
  into the software. The gene and variant information for all reported sections are interpreted directly from the
  uploaded vcf file. The user recognizes they are using PharmCAT at their own risk. For a detailed disclaimer see
  section IV.
</div>

<section>
  <h2>Sections</h2>
  <ol type="I">
    <li><a href="#genotypes">Genotype Summary</a></li>
    <li><a href="#guidelines">CPIC Recommendations</a></li>
    <li><a href="#genes">Allele Call Details</a></li>
    <li><a href="#disclaimer">Disclaimers</a></li>
  </ol>
</section>

<section id="genotypes">
  <h2>Genotype Summary</h2>

  <p>Genotypes called: 12 / 12 </p>

  <table>
    <thead>
    <tr>
      <th>Drugs <sup><a href="#genotypes-a">a</a></sup></th>
      <th>Gene</th>
      <th>Genotype</th>
      <th>Allele Functionality <sup><a href="#genotypes-b">b</a></sup></th>
      <th>Phenotype <sup><a href="#genotypes-b">b</a></sup></th>
      <th>Missing Variant Input <sup><a href="#genotypes-c">c</a></sup></th>
    </tr>
    </thead>
    <tbody>
    
      <tr>
        <td>
          <div class="drugName"><div class=" rxChange"><i class="fa fa-times rxChange" aria-hidden="true" title="Rx change"></i> <a href="#PA166114461">ivacaftor</a></div></div>
        </td>
        <td>
          <a href="#CFTR">CFTR</a>
        </td>
        <td>
          
            <div>No CPIC variants found</div>
          
        </td>
        <td>
          
            <div style="white-space: nowrap;">N/A</div>
          
        </td>
        <td>
          
            <div style="white-space: nowrap">N/A</div>
          
        </td>
        <td>
          No
        </td>
      </tr>
    
      <tr>
        <td>
          <div class="drugName"><div class=" rxChange"><i class="fa fa-times rxChange" aria-hidden="true" title="Rx change"></i> <a href="#PA166104999">imipramine</a></div></div>
        
          <div class="drugName"><div class=" rxChange"><i class="fa fa-times rxChange" aria-hidden="true" title="Rx change"></i> <a href="#PA166105007">clomipramine</a></div></div>
        
          <div class="drugName"><div class=" "><i class="fa fa-circle normal" aria-hidden="true" title="No Rx change"></i> <a href="#PA166127638">escitalopram</a></div></div>
        
          <div class="drugName"><div class=" "><i class="fa fa-circle normal" aria-hidden="true" title="No Rx change"></i> <a href="#PA166127638">citalopram</a></div></div>
        
          <div class="drugName"><div class=" "><i class="fa fa-circle normal" aria-hidden="true" title="No Rx change"></i> <a href="#PA166127639">sertraline</a></div></div>
        
          <div class="drugName"><div class=" "><i class="fa fa-circle normal" aria-hidden="true" title="No Rx change"></i> <a href="#PA166161537">voriconazole</a></div></div>
        
          <div class="drugName"><div class=" rxChange"><i class="fa fa-times rxChange" aria-hidden="true" title="Rx change"></i> <a href="#PA166105000">doxepin</a></div></div>
        
          <div class="drugName"><div class=" rxChange"><i class="fa fa-times rxChange" aria-hidden="true" title="Rx change"></i> <a href="#PA166105001">trimipramine</a></div></div>
        
          <div class="drugName"><div class=" "><i class="fa fa-circle normal" aria-hidden="true" title="No Rx change"></i> <a href="#PA166104948">clopidogrel</a></div></div>
        
          <div class="drugName"><div class=" rxChange"><i class="fa fa-times rxChange" aria-hidden="true" title="Rx change"></i> <a href="#PA166105006">amitriptyline</a></div></div>
        </td>
        <td>
          <a href="#CYP2C19">CYP2C19</a>
        </td>
        <td>
          
            <div>*1/*1</div>
          
        </td>
        <td>
          
            <div style="white-space: nowrap;">Two normal function alleles</div>
          
        </td>
        <td>
          
            <div style="white-space: nowrap">Normal Metabolizer</div>
          
        </td>
        <td>
          No
        </td>
      </tr>
    
      <tr>
        <td>
          <div class="drugName"><div class=" highlightDrug"><i class="fa fa-square highlight" aria-hidden="true" title="Consult guideline"></i> <a href="#PA166104949">warfarin</a></div></div>
        
          <div class="drugName"><div class=" "><i class="fa fa-circle normal" aria-hidden="true" title="No Rx change"></i> <a href="#PA166122806">phenytoin</a></div></div>
        </td>
        <td>
          <a href="#CYP2C9">CYP2C9</a>
        </td>
        <td>
          
            <div>*1/*1</div>
          
        </td>
        <td>
          
            <div style="white-space: nowrap;">Two normal function alleles</div>
          
        </td>
        <td>
          
            <div style="white-space: nowrap">Normal Metabolizer</div>
          
        </td>
        <td>
          No
        </td>
      </tr>
    
      <tr>
        <td>
          <div class="drugName"><div class=" rxChange"><i class="fa fa-times rxChange" aria-hidden="true" title="Rx change"></i> <a href="#PA166127637">fluvoxamine</a></div></div>
        
          <div class="drugName"><div class=" rxChange"><i class="fa fa-times rxChange" aria-hidden="true" title="Rx change"></i> <a href="#PA166104999">imipramine</a></div></div>
        
          <div class="drugName"><div class=" rxChange"><i class="fa fa-times rxChange" aria-hidden="true" title="Rx change"></i> <a href="#PA166105007">clomipramine</a></div></div>
        
          <div class="drugName"><div class=" rxChange"><i class="fa fa-times rxChange" aria-hidden="true" title="Rx change"></i> <a href="#PA166104998">nortriptyline</a></div></div>
        
          <div class="drugName"><div class=" rxChange"><i class="fa fa-times rxChange" aria-hidden="true" title="Rx change"></i> <a href="#PA166105002">desipramine</a></div></div>
        
          <div class="drugName"><div class=" "><i class="fa fa-circle normal" aria-hidden="true" title="No Rx change"></i> <a href="#PA166161955">tropisetron</a></div></div>
        
          <div class="drugName"><div class=" "><i class="fa fa-circle normal" aria-hidden="true" title="No Rx change"></i> <a href="#PA166161954">ondansetron</a></div></div>
        
          <div class="drugName"><div class=" rxChange"><i class="fa fa-times rxChange" aria-hidden="true" title="Rx change"></i> <a href="#PA166127636">paroxetine</a></div></div>
        
          <div class="drugName"><div class=" rxChange"><i class="fa fa-times rxChange" aria-hidden="true" title="Rx change"></i> <a href="#PA166104996">codeine</a></div></div>
        
          <div class="drugName"><div class=" rxChange"><i class="fa fa-times rxChange" aria-hidden="true" title="Rx change"></i> <a href="#PA166105000">doxepin</a></div></div>
        
          <div class="drugName"><div class=" rxChange"><i class="fa fa-times rxChange" aria-hidden="true" title="Rx change"></i> <a href="#PA166105001">trimipramine</a></div></div>
        
          <div class="drugName"><div class=" rxChange"><i class="fa fa-times rxChange" aria-hidden="true" title="Rx change"></i> <a href="#PA166105006">amitriptyline</a></div></div>
        </td>
        <td>
          <a href="#CYP2D6">CYP2D6</a><sup>&dagger;</sup>
        </td>
        <td>
          
            <div>*3/*4</div>
          
        </td>
        <td>
          
            <div style="white-space: nowrap;">Two no function alleles</div>
          
        </td>
        <td>
          
            <div style="white-space: nowrap">Poor Metabolizer</div>
          
        </td>
        <td>
          N/A
        </td>
      </tr>
    
      <tr>
        <td>
          <div class="drugName"><div class=" rxChange"><i class="fa fa-times rxChange" aria-hidden="true" title="Rx change"></i> <a href="#PA166124619">tacrolimus</a></div></div>
        </td>
        <td>
          <a href="#CYP3A5">CYP3A5</a><sup>&dagger;</sup>
        </td>
        <td>
          
            <div>*1/*1</div>
          
        </td>
        <td>
          
            <div style="white-space: nowrap;">Two normal function alleles</div>
          
        </td>
        <td>
          
            <div style="white-space: nowrap">Normal Metabolizer</div>
          
        </td>
        <td>
          No
        </td>
      </tr>
    
      <tr>
        <td>
          <div class="drugName"><div class=" highlightDrug"><i class="fa fa-square highlight" aria-hidden="true" title="Consult guideline"></i> <a href="#PA166104949">warfarin</a></div></div>
        </td>
        <td>
          <a href="#CYP4F2">CYP4F2</a>
        </td>
        <td>
          
            <div>*1/*1</div>
          
        </td>
        <td>
          
            <div style="white-space: nowrap;">Two normal function alleles</div>
          
        </td>
        <td>
          
            <div style="white-space: nowrap">N/A</div>
          
        </td>
        <td>
          No
        </td>
      </tr>
    
      <tr>
        <td>
          <div class="drugName"><div class=" "><i class="fa fa-circle normal" aria-hidden="true" title="No Rx change"></i> <a href="#PA166122686">fluorouracil</a></div></div>
        
          <div class="drugName"><div class=" "><i class="fa fa-circle normal" aria-hidden="true" title="No Rx change"></i> <a href="#PA166109594">capecitabine</a></div></div>
        </td>
        <td>
          <a href="#DPYD">DPYD</a><sup>&dagger;</sup>
        </td>
        <td>
          
            <div>No CPIC decreased or no function variant with strong or moderate evidence found</div>
          
        </td>
        <td>
          
            <div style="white-space: nowrap;">Two normal function alleles</div>
          
        </td>
        <td>
          
            <div style="white-space: nowrap">Normal Metabolizer (Activity Score&#x3D;2)</div>
          
        </td>
        <td>
          No
        </td>
      </tr>
    
      <tr>
        <td>
          <div class="drugName"><div class=" highlightDrug"><i class="fa fa-square highlight" aria-hidden="true" title="Consult guideline"></i> <a href="#PA166110235">peginterferon alfa-2a</a></div></div>
        
          <div class="drugName"><div class=" highlightDrug"><i class="fa fa-square highlight" aria-hidden="true" title="Consult guideline"></i> <a href="#PA166110235">peginterferon alfa-2b</a></div></div>
        
          <div class="drugName"><div class=" highlightDrug"><i class="fa fa-square highlight" aria-hidden="true" title="Consult guideline"></i> <a href="#PA166110235">ribavirin</a></div></div>
        </td>
        <td>
          <a href="#IFNL3">IFNL3</a><sup>&dagger;</sup>
        </td>
        <td>
          
            <div>rs12979860C/rs12979860C</div>
          
        </td>
        <td>
          
            <div style="white-space: nowrap;">N/A</div>
          
        </td>
        <td>
          
            <div style="white-space: nowrap">N/A</div>
          
        </td>
        <td>
          No
        </td>
      </tr>
    
      <tr>
        <td>
          <div class="drugName"><div class=" "><i class="fa fa-circle normal" aria-hidden="true" title="No Rx change"></i> <a href="#PA166105005">simvastatin</a></div></div>
        </td>
        <td>
          <a href="#SLCO1B1">SLCO1B1</a>
        </td>
        <td>
          
            <div>*1A/*1A</div>
          
        </td>
        <td>
          
            <div style="white-space: nowrap;">Two normal function alleles</div>
          
        </td>
        <td>
          
            <div style="white-space: nowrap">Normal Function</div>
          
        </td>
        <td>
          No
        </td>
      </tr>
    
      <tr>
        <td>
          <div class="drugName"><div class=" "><i class="fa fa-circle normal" aria-hidden="true" title="No Rx change"></i> <a href="#PA166104933">azathioprine</a></div></div>
        
          <div class="drugName"><div class=" "><i class="fa fa-circle normal" aria-hidden="true" title="No Rx change"></i> <a href="#PA166104965">thioguanine</a></div></div>
        
          <div class="drugName"><div class=" "><i class="fa fa-circle normal" aria-hidden="true" title="No Rx change"></i> <a href="#PA166104945">mercaptopurine</a></div></div>
        </td>
        <td>
          <a href="#TPMT">TPMT</a><sup>&dagger;</sup>
        </td>
        <td>
          
            <div>*1/*1</div>
          
        </td>
        <td>
          
            <div style="white-space: nowrap;">Two normal function alleles</div>
          
        </td>
        <td>
          
            <div style="white-space: nowrap">Normal Metabolizer</div>
          
        </td>
        <td>
          No
        </td>
      </tr>
    
      <tr>
        <td>
          <div class="drugName"><div class=" "><i class="fa fa-circle normal" aria-hidden="true" title="No Rx change"></i> <a href="#PA166128738">atazanavir</a></div></div>
        </td>
        <td>
          <a href="#UGT1A1">UGT1A1</a><sup>&dagger;</sup>
        </td>
        <td>
          
            <div>*1/*1</div>
          
        </td>
        <td>
          
            <div style="white-space: nowrap;">Two normal function alleles</div>
          
        </td>
        <td>
          
            <div style="white-space: nowrap">Normal Metabolizer</div>
          
        </td>
        <td>
          No
        </td>
      </tr>
    
      <tr>
        <td>
          <div class="drugName"><div class=" highlightDrug"><i class="fa fa-square highlight" aria-hidden="true" title="Consult guideline"></i> <a href="#PA166104949">warfarin</a></div></div>
        </td>
        <td>
          <a href="#VKORC1">VKORC1</a><sup>&dagger;</sup>
        </td>
        <td>
          
            <div>-1639A/-1639A</div>
          
        </td>
        <td>
          
            <div style="white-space: nowrap;">N/A</div>
          
        </td>
        <td>
          
            <div style="white-space: nowrap">N/A</div>
          
        </td>
        <td>
          No
        </td>
      </tr>
    
    </tbody>
  </table>

  <div class="footnote" id="genotypes-a">
    <sup>a</sup> The drugs are colored to indicate whether CPIC recommends a prescribing change based on the given genotype; highlighting is not based on CPIC classification of recommendation. When multiple diplotypes are possible for a gene, the drug is highlighted according to the highest level of prescribing change. <span class="rxChange"><i class="fa fa-times"></i> Red</span> indicates a prescribing change is recommended for the given diplotype. That is, the recommendation is different than ‘use label recommendation’ or ‘use recommended starting dose’, except for ivacaftor. <span class="rxPossibly"><i class="fa fa-warning"></i> Orange</span> indicates possible prescribing changes depending on additional information, e.g. pediatrics vs. adult, or the specific number of CYP2D6 normal alleles present (copy number). <span class="normal"><i class="fa fa-circle"></i> Green</span> indicates that there is no CPIC recommended prescribing change for the given diplotype, except for ivacaftor. <span class="highlight"><i class="fa fa-square"></i> Blue</span> indicates the specific guideline must be consulted because a CPIC recommended action cannot be provided based solely on diplotype (eg. warfarin and ribavirin/peginterferon).
  </div>
  <div class="footnote" id="genotypes-b">
    <sup>b</sup> Allele functionality and phenotype terms are based on the <a href="https://cpicpgx.org/wp-content/uploads/2016/01/CPIC_term_standardization_project_final_terms.pdf">CPIC term standardization</a> project, <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=27441996">PMID:27441996</a>. Guidelines published prior use the term 'extensive' instead of 'normal' metabolizer. CYP2C19*1/*17 is now classified as rapid metabolizer. Guidelines published prior group CYP2C19*1/*17 together with *17/*17 as ultrarapid metabolizer.
  </div>
  <div class="footnote" id="genotypes-c">
    <sup>c</sup> Indicates alleles not considered for the genotype calls due to missing variant information, please see Allele calls section. Alleles that could not be considered due to missing input might change the metabolizer phenotype and possible CPIC recommendation.
  </div>
  <div class="footnote">
    <sup>&dagger;</sup> Check the allele call details for this gene for more details about this call.
  </div>
  <div class="footnote">
    For a full list of disclaimers and limitations see the <a href="#disclaimer">Disclaimer section</a>.
  </div>
</section>

<section id="guidelines">
  <h2>CPIC Recommendations</h2>

  
    <section class="guideline">
      <h3 id="PA166105006">amitriptyline</h3>

      <section>
        <p>The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.</p>


        <p>The official guideline can be found on the <a href="https://cpicpgx.org">CPIC website</a>.</p>
      </section>

      

      <section>
        
          <div class="geneCall"><a href="#CYP2D6">CYP2D6: *3/*4</a> (from Astrolabe)</div>
          
        
          <div class="geneCall"><a href="#CYP2C19">CYP2C19: *1/*1</a></div>
          
        
      </section>

      

      <section>
        
      </section>

      
      
        
      

      

      
        
          <table>
            <thead>
            <tr><th>Type</th><th>Annotation</th></tr>
            </thead>
            <tbody>
            
              <tr><td>Allele Functionality</td><td>CYP2C19:Normal Function/Normal Function<br/>CYP2D6:No Function/No Function</td></tr>
            
              <tr><td>Phenotype</td><td>CYP2D6 Poor Metabolizer CYP2C19 Normal Metabolizer</td></tr>
            
              <tr><td>Implications</td><td><p><strong>For CYP2D6:</strong></p> <p>Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.</p> <p><strong>For CYP2C19:</strong></p> <p>Normal metabolism of tertiary amines.</p> </td></tr>
            
              <tr><td>Recommendations</td><td><p>Avoid amitriptyline use. If amitriptyline is warranted, consider 50% reduction of recommended starting dose.</p> <p><em>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended. Patients may receive an initial low dose of TCAs, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression.</em></p> </td></tr>
            
              <tr><td>Classification of Recommendation</td><td>Strong</td></tr>
            
            </tbody>
          </table>
        
      

      <section>
        
          <div class="footnote">Classification of recommendation might differ based on the availabilty of CYP2D6 or CYP2C19 genotypes only or a combination of CYP2D6 and CYP2C19 genotypes; see full guideline at cpicpgx.org.</div>
        
      </section>

      <section>
        <p>For more information see the <a href="https://www.pharmgkb.org/guideline/PA166105006">annotation on PharmGKB</a>.</p>
        
          <p>Citations:</p>
          <ul>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/27997040">Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update</a> [PMID:27997040] <em>Clinical pharmacology and therapeutics</em>. 2016.</li>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/23486447">Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants</a> [PMID:23486447] <em>Clinical pharmacology and therapeutics</em>. 2013.</li>
            
          </ul>
        
        <p><em>Guideline annotation last modified: </em>2016.12.14</p>
      </section>
    </section>
  
    <section class="guideline">
      <h3 id="PA166128738">atazanavir</h3>

      <section>
        <p>The CPIC dosing guideline recommends considering advising individuals who carry two decreased function <em>UGT1A1</em> alleles about a substantial likelihood of developing jaundice, which may cause non-adherence. The dosing guideline recommends that alternative agents be considered if the risk of non-adherence due to jaundice is high. The risk of discontinuation is low and very low for individuals carrying one, or no decreased function <em>UGT1A1</em> alleles, respectively.</p>


        <p>The official guideline can be found on the <a href="https://cpicpgx.org">CPIC website</a>.</p>
      </section>

      

      <section>
        
          <div class="geneCall"><a href="#UGT1A1">UGT1A1: *1/*1</a></div>
          
        
      </section>

      

      <section>
        
          <div class="alert alert-info">Unphased data: all variant alleles found are listed based on the vcf input and the UGT1A1 definition table. Phased data: the subject’s phased UGT1A1 genotype is listed. The CPIC recommendations are provided based on an exception logic. UGT1A1*28 and *80 are assumed in cis for unphased data, see http://pharmcat.org/ and the UGT1A1 gene section for details on *80.</div>
        
      </section>

      
      
        
      

      

      
        
          <table>
            <thead>
            <tr><th>Type</th><th>Annotation</th></tr>
            </thead>
            <tbody>
            
              <tr><td>Allele Functionality</td><td>UGT1A1:Normal Function/Normal Function</td></tr>
            
              <tr><td>Phenotype</td><td>Normal Metabolizer</td></tr>
            
              <tr><td>Implications</td><td><p>Reference UGT1A1 activity; very low likelihood of bilirubin-related discontinuation of atazanavir.</p> <p><em>“Reference” function refers to the UGT1A1 allele to which other alleles are compared.</em></p> </td></tr>
            
              <tr><td>Recommendations</td><td><p>There is no need to avoid prescribing of atazanavir based on <em>UGT1A1</em> genetic test result.</p> <p><em>Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient’s genotype makes this unlikely (less than about a 1 in 20 chance of stopping atazanavir because of jaundice).</em></p> </td></tr>
            
              <tr><td>Classification of Recommendation</td><td>Strong</td></tr>
            
            </tbody>
          </table>
        
      

      <section>
        
          <div class="footnote">These recommendations are for the use of atazanavir (boosted with either ritonavir or cobicistat) by UGT1A1 phenotype. All studies correlating UGT1A1 genotypes with atazanavir adverse events have involved ritonavir boosting. However, concentration-time profiles are equivalent when boosted with either cobicistat or ritonavir, and bilirubin-related adverse events including discontinuation of atazanavir occur in a similar percentage of patients prescribed atazanavir with cobicistat or ritonavir. Associations between UGT1A1 genotype, bilirubin elevations, and atazanavir discontinuation therefore almost certainly translate to atazanavir/cobicistat.</div>
        
      </section>

      <section>
        <p>For more information see the <a href="https://www.pharmgkb.org/guideline/PA166128738">annotation on PharmGKB</a>.</p>
        
          <p>Citations:</p>
          <ul>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/26417955">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing</a> [PMID:26417955] <em>Clinical pharmacology and therapeutics</em>. 2015.</li>
            
          </ul>
        
        <p><em>Guideline annotation last modified: </em>2015.09.18</p>
      </section>
    </section>
  
    <section class="guideline">
      <h3 id="PA166104933">azathioprine</h3>

      <section>
        <p>Consider an alternate agent or extreme dose reduction of azathioprine for patients with low or deficient TPMT activity.  Start at 30-70% of target dose for patients with intermediate enzyme activity.</p>


        <p>The official guideline can be found on the <a href="https://cpicpgx.org">CPIC website</a>.</p>
      </section>

      

      <section>
        
          <div class="geneCall"><a href="#TPMT">TPMT: *1/*1</a></div>
          
        
      </section>

      

      <section>
        
      </section>

      
      
        
      

      

      
        
          <table>
            <thead>
            <tr><th>Type</th><th>Annotation</th></tr>
            </thead>
            <tbody>
            
              <tr><td>Allele Functionality</td><td>TPMT:Normal Function/Normal Function</td></tr>
            
              <tr><td>Phenotype</td><td>Normal Metabolizer</td></tr>
            
              <tr><td>Implications</td><td><p>Lower concentrations of TGN metabolites, higher methylTIMP, this is the &quot;normal&quot; pattern</p> </td></tr>
            
              <tr><td>Recommendations</td><td><p>Start with normal starting dose (e.g., 2-3 mg/kg/d) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady state after each dose adjustment.</p> </td></tr>
            
              <tr><td>Classification of Recommendation</td><td>Strong</td></tr>
            
            </tbody>
          </table>
        
      

      <section>
        
      </section>

      <section>
        <p>For more information see the <a href="https://www.pharmgkb.org/guideline/PA166104933">annotation on PharmGKB</a>.</p>
        
          <p>Citations:</p>
          <ul>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/23422873">Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update</a> [PMID:23422873] <em>Clinical pharmacology and therapeutics</em>. 2013.</li>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21270794">Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing</a> [PMID:21270794] <em>Clinical pharmacology and therapeutics</em>. 2011.</li>
            
          </ul>
        
        <p><em>Guideline annotation last modified: </em>2016.05.10</p>
      </section>
    </section>
  
    <section class="guideline">
      <h3 id="PA166109594">capecitabine</h3>

      <section>
        <p>The CPIC Dosing Guideline for 5-fluorouracil and capecitabine recommends an alternative drug for patients who are DPYD poor metabolizers with an activity score of 0. In those who are poor metabolizers with an activity score of 0.5, an alternative drug is also recommended, but if this is not considered a suitable therapeutic option, 5-fluorouracil or capecitabine should be administered at a strongly reduced dose with early therapeutic drug monitoring. Patients who are intermediate metabolizers with an activity score of 1 or 1.5 should receive a dose reduction of 50% and 25%-50%, respectively.</p>


        <p>The official guideline can be found on the <a href="https://cpicpgx.org">CPIC website</a>.</p>
      </section>

      

      <section>
        
          <div class="geneCall"><a href="#DPYD">DPYD: No CPIC decreased or no function variant with strong or moderate evidence found</a></div>
          
        
      </section>

      

      <section>
        
          <div class="alert alert-info">The 2017 CPIC DPYD guideline update includes normal function variants with strong, moderate or in vitro data only evidence. These variants are not included in the PharmCAT DPYD gene definition table. The CPIC DPYD functionality table includes further no and decreased function variants with 'In vitro data only and/or limited clinical/ex vivo data' evidence. According to the guideline, to date, there are no studies linking the variants listed in the “in vitro data only and/or limited clinical/ex vivo data” category as decreased or no function variants directly to toxicity related to fluoropyrimidines and therefore, these variants are not specifically included in the CPIC recommendations. These variants are not included in the PharmCAT DPYD gene definition table. Refer to the DPYD gene section for a list of these variants.</div>
        
      </section>

      
      
        
      

      

      
        
          <table>
            <thead>
            <tr><th>Type</th><th>Annotation</th></tr>
            </thead>
            <tbody>
            
              <tr><td>Allele Functionality</td><td>DPYD:Normal Function/Normal Function</td></tr>
            
              <tr><td>Phenotype</td><td>Normal Metabolizer (Activity Score=2)</td></tr>
            
              <tr><td>Implications</td><td><p>Normal DPD activity and &quot;normal&quot; risk for fluoropyrimidine toxicity.</p> </td></tr>
            
              <tr><td>Recommendations</td><td><p>Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration.</p> </td></tr>
            
              <tr><td>Classification of Recommendation</td><td>Strong</td></tr>
            
            </tbody>
          </table>
        
      

      <section>
        
      </section>

      <section>
        <p>For more information see the <a href="https://www.pharmgkb.org/guideline/PA166109594">annotation on PharmGKB</a>.</p>
        
          <p>Citations:</p>
          <ul>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/29152729">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update</a> [PMID:29152729] <em>Clinical pharmacology and therapeutics</em>. 2017.</li>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/23988873">Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing</a> [PMID:23988873] <em>Clinical pharmacology and therapeutics</em>. 2013.</li>
            
          </ul>
        
        <p><em>Guideline annotation last modified: </em>2017.11.13</p>
      </section>
    </section>
  
    <section class="guideline">
      <h3 id="PA166127638">escitalopram, citalopram</h3>

      <section>
        <p>The CPIC Dosing Guideline for the selective serotonin reuptake inhibitors citalopram and escitalopram recommends an alternative drug not predominantly metabolized by CYP2C19 for CYP2C19 ultrarapid metabolizers. For CYP2C19 poor metabolizers, consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.</p>


        <p>The official guideline can be found on the <a href="https://cpicpgx.org">CPIC website</a>.</p>
      </section>

      

      <section>
        
          <div class="geneCall"><a href="#CYP2C19">CYP2C19: *1/*1</a></div>
          
        
      </section>

      

      <section>
        
      </section>

      
      
        
      

      

      
        
          <table>
            <thead>
            <tr><th>Type</th><th>Annotation</th></tr>
            </thead>
            <tbody>
            
              <tr><td>Allele Functionality</td><td>CYP2C19:Normal Function/Normal Function</td></tr>
            
              <tr><td>Phenotype</td><td>Normal Metabolizer</td></tr>
            
              <tr><td>Implications</td><td><p>Normal metabolism</p> </td></tr>
            
              <tr><td>Recommendations</td><td><p>Initiate therapy with recommended starting dose.</p> </td></tr>
            
              <tr><td>Classification of Recommendation</td><td>Strong</td></tr>
            
            </tbody>
          </table>
        
      

      <section>
        
      </section>

      <section>
        <p>For more information see the <a href="https://www.pharmgkb.org/guideline/PA166127638">annotation on PharmGKB</a>.</p>
        
          <p>Citations:</p>
          <ul>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/25974703">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors</a> [PMID:25974703] <em>Clinical pharmacology and therapeutics</em>. 2015.</li>
            
          </ul>
        
        <p><em>Guideline annotation last modified: </em>2015.05.11</p>
      </section>
    </section>
  
    <section class="guideline">
      <h3 id="PA166105007">clomipramine</h3>

      <section>
        <p>Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including clomipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.</p>


        <p>The official guideline can be found on the <a href="https://cpicpgx.org">CPIC website</a>.</p>
      </section>

      

      <section>
        
          <div class="geneCall"><a href="#CYP2D6">CYP2D6: *3/*4</a> (from Astrolabe)</div>
          
        
          <div class="geneCall"><a href="#CYP2C19">CYP2C19: *1/*1</a></div>
          
        
      </section>

      

      <section>
        
      </section>

      
      
        
      

      

      
        
          <table>
            <thead>
            <tr><th>Type</th><th>Annotation</th></tr>
            </thead>
            <tbody>
            
              <tr><td>Allele Functionality</td><td>CYP2C19:Normal Function/Normal Function<br/>CYP2D6:No Function/No Function</td></tr>
            
              <tr><td>Phenotype</td><td>CYP2D6 Poor Metabolizer CYP2C19 Normal Metabolizer</td></tr>
            
              <tr><td>Implications</td><td><p><strong>For CYP2D6:</strong></p> <p>Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.</p> <p><strong>For CYP2C19:</strong></p> <p>Normal metabolism of tertiary amines.</p> </td></tr>
            
              <tr><td>Recommendations</td><td><p>The dosing recommendations are based on studies focusing on amitriptyline. Because tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply these guidelines to other tertiary amines including clomipramine, doxepin, imipramine and trimipramine.</p> <p><strong>Avoid TCA use. If TCAs are warranted, consider 50% reduction of recommended starting dose.</strong></p> <p><em>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended. Patients may receive an initial low dose of TCAs, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression.</em></p> </td></tr>
            
              <tr><td>Classification of Recommendation</td><td>Optional</td></tr>
            
            </tbody>
          </table>
        
      

      <section>
        
          <div class="footnote">Classification of recommendation might differ based on the availabilty of CYP2D6 or CYP2C19 genotypes only or a combination of CYP2D6 and CYP2C19 genotypes; see full guideline at cpicpgx.org.</div>
        
      </section>

      <section>
        <p>For more information see the <a href="https://www.pharmgkb.org/guideline/PA166105007">annotation on PharmGKB</a>.</p>
        
          <p>Citations:</p>
          <ul>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/27997040">Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update</a> [PMID:27997040] <em>Clinical pharmacology and therapeutics</em>. 2016.</li>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/23486447">Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants</a> [PMID:23486447] <em>Clinical pharmacology and therapeutics</em>. 2013.</li>
            
          </ul>
        
        <p><em>Guideline annotation last modified: </em>2016.12.14</p>
      </section>
    </section>
  
    <section class="guideline">
      <h3 id="PA166104948">clopidogrel</h3>

      <section>
        <p>The CPIC Dosing Guideline for clopidogrel recommends an alternative antiplatelet therapy (e.g., prasugrel, ticagrelor) for CYP2C19 poor or intermediate metabolizers if there is no contraindication.</p>


        <p>The official guideline can be found on the <a href="https://cpicpgx.org">CPIC website</a>.</p>
      </section>

      

      <section>
        
          <div class="geneCall"><a href="#CYP2C19">CYP2C19: *1/*1</a></div>
          
        
      </section>

      

      <section>
        
      </section>

      
      
        
      

      

      
        
          <table>
            <thead>
            <tr><th>Type</th><th>Annotation</th></tr>
            </thead>
            <tbody>
            
              <tr><td>Allele Functionality</td><td>CYP2C19:Normal Function/Normal Function</td></tr>
            
              <tr><td>Phenotype</td><td>Normal Metabolizer</td></tr>
            
              <tr><td>Implications</td><td><p>Normal platelet inhibition; normal residual platelet aggregation</p> </td></tr>
            
              <tr><td>Recommendations</td><td><p>Clopidogrel - label recommended dosage and administration</p> </td></tr>
            
              <tr><td>Classification of Recommendation</td><td>Strong</td></tr>
            
            </tbody>
          </table>
        
      

      <section>
        
          <div class="footnote">Antiplatelet therapy recommendations are based on CYP2C19 status when considering clopidogrel for acute coronary syndrome (ACS patients undergoing percutaneous coronary intervention (PCI)). CPIC guidelines reflect the alleles/genotypes known and considered by the guideline authors for inclusion by the time of publication. CPIC guidelines are periodically updated - see cpicpgx.org.</div>
        
      </section>

      <section>
        <p>For more information see the <a href="https://www.pharmgkb.org/guideline/PA166104948">annotation on PharmGKB</a>.</p>
        
          <p>Citations:</p>
          <ul>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/23698643">Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy: 2013 Update</a> [PMID:23698643] <em>Clinical pharmacology and therapeutics</em>. 2013.</li>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21716271">Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy</a> [PMID:21716271] <em>Clinical pharmacology and therapeutics</em>. 2011.</li>
            
          </ul>
        
        <p><em>Guideline annotation last modified: </em>2013.05.22</p>
      </section>
    </section>
  
    <section class="guideline">
      <h3 id="PA166104996">codeine</h3>

      <section>
        <p>Alternate analgesics are recommended for CYP2D6 ultrarapid and poor metabolizers. A label recommended age- or weight-specific codeine dose is warranted for CYP2D6 extensive and intermediate metabolizers.</p>


        <p>The official guideline can be found on the <a href="https://cpicpgx.org">CPIC website</a>.</p>
      </section>

      

      <section>
        
          <div class="geneCall"><a href="#CYP2D6">CYP2D6: *3/*4</a> (from Astrolabe)</div>
          
        
      </section>

      

      <section>
        
      </section>

      
      
        
      

      

      
        
          <table>
            <thead>
            <tr><th>Type</th><th>Annotation</th></tr>
            </thead>
            <tbody>
            
              <tr><td>Allele Functionality</td><td>CYP2D6:No Function/No Function</td></tr>
            
              <tr><td>Phenotype</td><td>Poor Metabolizer</td></tr>
            
              <tr><td>Activity Score</td><td><p>0</p> </td></tr>
            
              <tr><td>Implications</td><td><p>Greatly reduced morphine formation following codeine administration, leading to insufficient pain relief</p> </td></tr>
            
              <tr><td>Recommendations</td><td><p>Avoid codeine use due to lack of efficacy.</p> <p><em>Considerations for alternative opioids: Alternatives that are not affected by this CYP2D6 phenotype include morphine and non-opioid analgesics. Tramadol, and to a lesser extent hydrocodone and oxycodone, are not good alternatives because their metabolism is affected by CYP2D6 activity; these agents should be avoided. There is substantial evidence for decreased efficacy of tramadol in poor metabolizers and a single case report of toxicity in an ultrarapid metabolizer with renal impairment following tramadol post-surgery. Use of other analgesics in CYP2D6 poor and ultrarapid metabolizers may therefore be preferable. Some other opioid analgesics are metabolized by CYP2D6, such as hydrocodone and oxycodone. To avoid treatment complications, opioids that are not metabolized by CYP2D6, including morphine, oxymorphone, buprenorphine, fentanyl, methadone and hydromorphone, along with non-opioid analgesics, may be considered as alternatives for use in CYP2D6 poor and ultrarapid metabolizers.</em></p> </td></tr>
            
              <tr><td>Classification of Recommendation</td><td>Strong</td></tr>
            
            </tbody>
          </table>
        
      

      <section>
        
      </section>

      <section>
        <p>For more information see the <a href="https://www.pharmgkb.org/guideline/PA166104996">annotation on PharmGKB</a>.</p>
        
          <p>Citations:</p>
          <ul>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/24458010">Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450 2D6 (CYP2D6) genotype and codeine therapy: 2014 Update</a> [PMID:24458010] <em>Clinical pharmacology and therapeutics</em>. 2014.</li>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/22205192">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype</a> [PMID:22205192] <em>Clinical pharmacology and therapeutics</em>. 2011.</li>
            
          </ul>
        
        <p><em>Guideline annotation last modified: </em>2017.05.02</p>
      </section>
    </section>
  
    <section class="guideline">
      <h3 id="PA166105002">desipramine</h3>

      <section>
        <p>Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline/nortriptyline and CYP2C19, CYP2D6 to other tricyclics including desipramine. The CPIC Dosing Guideline update for nortriptyline recommends a 25% dose reduction for CYP2D6 intermediate metabolizers. For CYP2D6 ultrarapid or poor metabolizers, an alternative drug should be considered. If nortriptyline is warranted, consider a 50% dose reduction in CYP2D6 poor metabolizers.</p>


        <p>The official guideline can be found on the <a href="https://cpicpgx.org">CPIC website</a>.</p>
      </section>

      

      <section>
        
          <div class="geneCall"><a href="#CYP2D6">CYP2D6: *3/*4</a> (from Astrolabe)</div>
          
        
      </section>

      

      <section>
        
      </section>

      
      
        
      

      

      
        
          <table>
            <thead>
            <tr><th>Type</th><th>Annotation</th></tr>
            </thead>
            <tbody>
            
              <tr><td>Allele Functionality</td><td>CYP2D6:No Function/No Function</td></tr>
            
              <tr><td>Phenotype</td><td>Poor Metabolizer</td></tr>
            
              <tr><td>Activity Score</td><td><p>0</p> </td></tr>
            
              <tr><td>Implications</td><td><p>Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.</p> </td></tr>
            
              <tr><td>Recommendations</td><td><p>Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider 50% reduction of recommended starting dose.g Utilize therapeutic drug monitoring to guide dose adjustments.</p> <p><em>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression.</em></p> </td></tr>
            
              <tr><td>Classification of Recommendation</td><td>Optional</td></tr>
            
            </tbody>
          </table>
        
      

      <section>
        
      </section>

      <section>
        <p>For more information see the <a href="https://www.pharmgkb.org/guideline/PA166105002">annotation on PharmGKB</a>.</p>
        
          <p>Citations:</p>
          <ul>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/27997040">Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update</a> [PMID:27997040] <em>Clinical pharmacology and therapeutics</em>. 2016.</li>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/23486447">Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants</a> [PMID:23486447] <em>Clinical pharmacology and therapeutics</em>. 2013.</li>
            
          </ul>
        
        <p><em>Guideline annotation last modified: </em>2016.12.14</p>
      </section>
    </section>
  
    <section class="guideline">
      <h3 id="PA166105000">doxepin</h3>

      <section>
        <p>Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including doxepin. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.</p>


        <p>The official guideline can be found on the <a href="https://cpicpgx.org">CPIC website</a>.</p>
      </section>

      

      <section>
        
          <div class="geneCall"><a href="#CYP2D6">CYP2D6: *3/*4</a> (from Astrolabe)</div>
          
        
          <div class="geneCall"><a href="#CYP2C19">CYP2C19: *1/*1</a></div>
          
        
      </section>

      

      <section>
        
      </section>

      
      
        
      

      

      
        
          <table>
            <thead>
            <tr><th>Type</th><th>Annotation</th></tr>
            </thead>
            <tbody>
            
              <tr><td>Allele Functionality</td><td>CYP2C19:Normal Function/Normal Function<br/>CYP2D6:No Function/No Function</td></tr>
            
              <tr><td>Phenotype</td><td>CYP2D6 Poor Metabolizer CYP2C19 Normal Metabolizer</td></tr>
            
              <tr><td>Implications</td><td><p><strong>For CYP2D6:</strong></p> <p>Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.</p> <p><strong>For CYP2C19:</strong></p> <p>Normal metabolism of tertiary amines.</p> </td></tr>
            
              <tr><td>Recommendations</td><td><p>The dosing recommendations are based on studies focusing on amitriptyline. Because tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply these guidelines to other tertiary amines including clomipramine, doxepin, imipramine and trimipramine.</p> <p><strong>Avoid TCA use. If TCAs are warranted, consider 50% reduction of recommended starting dose.</strong></p> <p><em>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended. Patients may receive an initial low dose of TCAs, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression.</em></p> </td></tr>
            
              <tr><td>Classification of Recommendation</td><td>Optional</td></tr>
            
            </tbody>
          </table>
        
      

      <section>
        
          <div class="footnote">Classification of recommendation might differ based on the availabilty of CYP2D6 or CYP2C19 genotypes only or a combination of CYP2D6 and CYP2C19 genotypes; see full guideline at cpicpgx.org.</div>
        
      </section>

      <section>
        <p>For more information see the <a href="https://www.pharmgkb.org/guideline/PA166105000">annotation on PharmGKB</a>.</p>
        
          <p>Citations:</p>
          <ul>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/27997040">Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update</a> [PMID:27997040] <em>Clinical pharmacology and therapeutics</em>. 2016.</li>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/23486447">Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants</a> [PMID:23486447] <em>Clinical pharmacology and therapeutics</em>. 2013.</li>
            
          </ul>
        
        <p><em>Guideline annotation last modified: </em>2016.12.14</p>
      </section>
    </section>
  
    <section class="guideline">
      <h3 id="PA166122686">fluorouracil</h3>

      <section>
        <p>The CPIC Dosing Guideline for 5-fluorouracil and capecitabine recommends an alternative drug for patients who are DPYD poor metabolizers with an activity score of 0. In those who are poor metabolizers with an activity score of 0.5, an alternative drug is also recommended, but if this is not considered a suitable therapeutic option, 5-fluorouracil or capecitabine should be administered at a strongly reduced dose with early therapeutic drug monitoring. Patients who are intermediate metabolizers with an activity score of 1 or 1.5 should receive a dose reduction of 50% and 25%-50%, respectively.</p>


        <p>The official guideline can be found on the <a href="https://cpicpgx.org">CPIC website</a>.</p>
      </section>

      

      <section>
        
          <div class="geneCall"><a href="#DPYD">DPYD: No CPIC decreased or no function variant with strong or moderate evidence found</a></div>
          
        
      </section>

      

      <section>
        
          <div class="alert alert-info">The 2017 CPIC DPYD guideline update includes normal function variants with strong, moderate or in vitro data only evidence. These variants are not included in the PharmCAT DPYD gene definition table. The CPIC DPYD functionality table includes further no and decreased function variants with 'In vitro data only and/or limited clinical/ex vivo data' evidence. According to the guideline, to date, there are no studies linking the variants listed in the “in vitro data only and/or limited clinical/ex vivo data” category as decreased or no function variants directly to toxicity related to fluoropyrimidines and therefore, these variants are not specifically included in the CPIC recommendations. These variants are not included in the PharmCAT DPYD gene definition table. Refer to the DPYD gene section for a list of these variants.</div>
        
      </section>

      
      
        
      

      

      
        
          <table>
            <thead>
            <tr><th>Type</th><th>Annotation</th></tr>
            </thead>
            <tbody>
            
              <tr><td>Allele Functionality</td><td>DPYD:Normal Function/Normal Function</td></tr>
            
              <tr><td>Phenotype</td><td>Normal Metabolizer (Activity Score=2)</td></tr>
            
              <tr><td>Implications</td><td><p>Normal DPD activity and &quot;normal&quot; risk for fluoropyrimidine toxicity.</p> </td></tr>
            
              <tr><td>Recommendations</td><td><p>Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration.</p> </td></tr>
            
              <tr><td>Classification of Recommendation</td><td>Strong</td></tr>
            
            </tbody>
          </table>
        
      

      <section>
        
      </section>

      <section>
        <p>For more information see the <a href="https://www.pharmgkb.org/guideline/PA166122686">annotation on PharmGKB</a>.</p>
        
          <p>Citations:</p>
          <ul>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/29152729">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update</a> [PMID:29152729] <em>Clinical pharmacology and therapeutics</em>. 2017.</li>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/23988873">Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing</a> [PMID:23988873] <em>Clinical pharmacology and therapeutics</em>. 2013.</li>
            
          </ul>
        
        <p><em>Guideline annotation last modified: </em>2017.11.28</p>
      </section>
    </section>
  
    <section class="guideline">
      <h3 id="PA166127637">fluvoxamine</h3>

      <section>
        <p>The CPIC Dosing Guideline for the selective serotonin reuptake inhibitor fluvoxamine recommends to consider a 25-50% reduction of recommended starting dose and titrate to response or use an alternative drug not metabolized by CYP2D6 for CYP2D6 poor metabolizers.</p>


        <p>The official guideline can be found on the <a href="https://cpicpgx.org">CPIC website</a>.</p>
      </section>

      

      <section>
        
          <div class="geneCall"><a href="#CYP2D6">CYP2D6: *3/*4</a> (from Astrolabe)</div>
          
        
      </section>

      

      <section>
        
      </section>

      
      
        
      

      

      
        
          <table>
            <thead>
            <tr><th>Type</th><th>Annotation</th></tr>
            </thead>
            <tbody>
            
              <tr><td>Allele Functionality</td><td>CYP2D6:No Function/No Function</td></tr>
            
              <tr><td>Phenotype</td><td>Poor Metabolizer</td></tr>
            
              <tr><td>Activity Score</td><td><p>0</p> </td></tr>
            
              <tr><td>Implications</td><td><p>Greatly reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects.</p> </td></tr>
            
              <tr><td>Recommendations</td><td><p>Consider a 25-50% reduction of recommended starting dose and titrate to response or use an alternative drug not metabolized by CYP2D6.</p> <p><em>Dose extrapolations based on differences in pharmacokinetic parameters between phenotype groups suggest a 30% dose reduction of fluvoxamine. However, a 30% decrease in dose may not be feasible given the dosage forms, therefore, decreasing the starting dose of fluvoxamine by 25-50% should be considered. Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.</em></p> </td></tr>
            
              <tr><td>Classification of Recommendation</td><td>Optional</td></tr>
            
            </tbody>
          </table>
        
      

      <section>
        
      </section>

      <section>
        <p>For more information see the <a href="https://www.pharmgkb.org/guideline/PA166127637">annotation on PharmGKB</a>.</p>
        
          <p>Citations:</p>
          <ul>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/25974703">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors</a> [PMID:25974703] <em>Clinical pharmacology and therapeutics</em>. 2015.</li>
            
          </ul>
        
        <p><em>Guideline annotation last modified: </em>2015.05.08</p>
      </section>
    </section>
  
    <section class="guideline">
      <h3 id="PA166104999">imipramine</h3>

      <section>
        <p>Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including imipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.</p>


        <p>The official guideline can be found on the <a href="https://cpicpgx.org">CPIC website</a>.</p>
      </section>

      

      <section>
        
          <div class="geneCall"><a href="#CYP2D6">CYP2D6: *3/*4</a> (from Astrolabe)</div>
          
        
          <div class="geneCall"><a href="#CYP2C19">CYP2C19: *1/*1</a></div>
          
        
      </section>

      

      <section>
        
      </section>

      
      
        
      

      

      
        
          <table>
            <thead>
            <tr><th>Type</th><th>Annotation</th></tr>
            </thead>
            <tbody>
            
              <tr><td>Allele Functionality</td><td>CYP2C19:Normal Function/Normal Function<br/>CYP2D6:No Function/No Function</td></tr>
            
              <tr><td>Phenotype</td><td>CYP2D6 Poor Metabolizer CYP2C19 Normal Metabolizer</td></tr>
            
              <tr><td>Implications</td><td><p><strong>For CYP2D6:</strong></p> <p>Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.</p> <p><strong>For CYP2C19:</strong></p> <p>Normal metabolism of tertiary amines.</p> </td></tr>
            
              <tr><td>Recommendations</td><td><p>The dosing recommendations are based on studies focusing on amitriptyline. Because tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply these guidelines to other tertiary amines including clomipramine, doxepin, imipramine and trimipramine.</p> <p><strong>Avoid TCA use. If TCAs are warranted, consider 50% reduction of recommended starting dose.</strong></p> <p><em>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended. Patients may receive an initial low dose of TCAs, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression.</em></p> </td></tr>
            
              <tr><td>Classification of Recommendation</td><td>Optional</td></tr>
            
            </tbody>
          </table>
        
      

      <section>
        
          <div class="footnote">Classification of recommendation might differ based on the availabilty of CYP2D6 or CYP2C19 genotypes only or a combination of CYP2D6 and CYP2C19 genotypes; see full guideline at cpicpgx.org.</div>
        
      </section>

      <section>
        <p>For more information see the <a href="https://www.pharmgkb.org/guideline/PA166104999">annotation on PharmGKB</a>.</p>
        
          <p>Citations:</p>
          <ul>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/27997040">Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update</a> [PMID:27997040] <em>Clinical pharmacology and therapeutics</em>. 2016.</li>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/23486447">Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants</a> [PMID:23486447] <em>Clinical pharmacology and therapeutics</em>. 2013.</li>
            
          </ul>
        
        <p><em>Guideline annotation last modified: </em>2016.12.14</p>
      </section>
    </section>
  
    <section class="guideline">
      <h3 id="PA166114461">ivacaftor</h3>

      <section>
        <p>Ivacaftor treatment is recommended only in cystic fibrosis (CF) patients that are either homozygous or heterozygous for certain <em>CFTR</em> variants.  See full guideline for disclaimers, further details and supporting evidence.</p>


        <p>The official guideline can be found on the <a href="https://cpicpgx.org">CPIC website</a>.</p>
      </section>

      

      <section>
        
          <div class="geneCall"><a href="#CFTR">CFTR: No CPIC variants found</a></div>
          
        
      </section>

      

      <section>
        
      </section>

      
      
        
      

      

      
        
          <table>
            <thead>
            <tr><th>Type</th><th>Annotation</th></tr>
            </thead>
            <tbody>
            
              <tr><td>Recommendations</td><td><p>This guideline does not contain recommendations for this allele combination.</p> </td></tr>
            
              <tr><td>Classification of Recommendation</td><td>N/A</td></tr>
            
            </tbody>
          </table>
        
      

      <section>
        
      </section>

      <section>
        <p>For more information see the <a href="https://www.pharmgkb.org/guideline/PA166114461">annotation on PharmGKB</a>.</p>
        
          <p>Citations:</p>
          <ul>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/24598717">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype</a> [PMID:24598717] <em>Clinical pharmacology and therapeutics</em>. 2014.</li>
            
          </ul>
        
        <p><em>Guideline annotation last modified: </em>2017.06.02</p>
      </section>
    </section>
  
    <section class="guideline">
      <h3 id="PA166104945">mercaptopurine</h3>

      <section>
        <p>Start with reduced doses of mercaptopurine for patients with one nonfunctional TPMT allele, or drastically reduced doses for patients with malignancy and two nonfunctional alleles; adjust dose based on degree of myelosuppression and disease-specific guidelines. Consider alternative nonthiopurine immunosuppressant therapy for patients with nonmalignant conditions and two nonfunctional alleles.</p>


        <p>The official guideline can be found on the <a href="https://cpicpgx.org">CPIC website</a>.</p>
      </section>

      

      <section>
        
          <div class="geneCall"><a href="#TPMT">TPMT: *1/*1</a></div>
          
        
      </section>

      

      <section>
        
      </section>

      
      
        
      

      

      
        
          <table>
            <thead>
            <tr><th>Type</th><th>Annotation</th></tr>
            </thead>
            <tbody>
            
              <tr><td>Allele Functionality</td><td>TPMT:Normal Function/Normal Function</td></tr>
            
              <tr><td>Phenotype</td><td>Normal Metabolizer</td></tr>
            
              <tr><td>Implications</td><td><p>Lower concentrations of TGN metabolites, higher methylTIMP, this is the &quot;normal&quot; pattern</p> </td></tr>
            
              <tr><td>Recommendations</td><td><p>Start with normal starting dose (e.g., 75 mg/m2/d or 1.5 mg/kg/d) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow 2 weeks to reach steady state after each dose adjustment.</p> </td></tr>
            
              <tr><td>Classification of Recommendation</td><td>Strong</td></tr>
            
            </tbody>
          </table>
        
      

      <section>
        
      </section>

      <section>
        <p>For more information see the <a href="https://www.pharmgkb.org/guideline/PA166104945">annotation on PharmGKB</a>.</p>
        
          <p>Citations:</p>
          <ul>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/23422873">Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update</a> [PMID:23422873] <em>Clinical pharmacology and therapeutics</em>. 2013.</li>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21270794">Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing</a> [PMID:21270794] <em>Clinical pharmacology and therapeutics</em>. 2011.</li>
            
          </ul>
        
        <p><em>Guideline annotation last modified: </em>2016.05.10</p>
      </section>
    </section>
  
    <section class="guideline">
      <h3 id="PA166104998">nortriptyline</h3>

      <section>
        <p>The CPIC Dosing Guideline update for nortriptyline recommends a 25% dose reduction for CYP2D6 intermediate metabolizers. For CYP2D6 ultrarapid or poor metabolizers, an alternative drug should be considered. If nortriptyline is warranted, consider a 50% dose reduction in CYP2D6 poor metabolizers.</p>


        <p>The official guideline can be found on the <a href="https://cpicpgx.org">CPIC website</a>.</p>
      </section>

      

      <section>
        
          <div class="geneCall"><a href="#CYP2D6">CYP2D6: *3/*4</a> (from Astrolabe)</div>
          
        
      </section>

      

      <section>
        
      </section>

      
      
        
      

      

      
        
          <table>
            <thead>
            <tr><th>Type</th><th>Annotation</th></tr>
            </thead>
            <tbody>
            
              <tr><td>Allele Functionality</td><td>CYP2D6:No Function/No Function</td></tr>
            
              <tr><td>Phenotype</td><td>Poor Metabolizer</td></tr>
            
              <tr><td>Activity Score</td><td><p>0</p> </td></tr>
            
              <tr><td>Implications</td><td><p>Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.</p> </td></tr>
            
              <tr><td>Recommendations</td><td><p>Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider 50% reduction of recommended starting dose.g Utilize therapeutic drug monitoring to guide dose adjustments.</p> <p><em>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression.</em></p> </td></tr>
            
              <tr><td>Classification of Recommendation</td><td>Strong</td></tr>
            
            </tbody>
          </table>
        
      

      <section>
        
      </section>

      <section>
        <p>For more information see the <a href="https://www.pharmgkb.org/guideline/PA166104998">annotation on PharmGKB</a>.</p>
        
          <p>Citations:</p>
          <ul>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/27997040">Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update</a> [PMID:27997040] <em>Clinical pharmacology and therapeutics</em>. 2016.</li>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/23486447">Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants</a> [PMID:23486447] <em>Clinical pharmacology and therapeutics</em>. 2013.</li>
            
          </ul>
        
        <p><em>Guideline annotation last modified: </em>2016.12.14</p>
      </section>
    </section>
  
    <section class="guideline">
      <h3 id="PA166161954">ondansetron</h3>

      <section>
        <p>The CPIC dosing guideline for ondansetron recommends selecting an alternate drug for CYP2D6 ultrarapid metabolizers.  It is recommended that the alternate drug not be predominantly metabolized by CYP2D6 (eg. granisetron).</p>


        <p>The official guideline can be found on the <a href="https://cpicpgx.org">CPIC website</a>.</p>
      </section>

      

      <section>
        
          <div class="geneCall"><a href="#CYP2D6">CYP2D6: *3/*4</a> (from Astrolabe)</div>
          
        
      </section>

      

      <section>
        
      </section>

      
      
        
      

      

      
        
          <table>
            <thead>
            <tr><th>Type</th><th>Annotation</th></tr>
            </thead>
            <tbody>
            
              <tr><td>Allele Functionality</td><td>CYP2D6:No Function/No Function</td></tr>
            
              <tr><td>Phenotype</td><td>Poor Metabolizer</td></tr>
            
              <tr><td>Activity Score</td><td><p>0</p> </td></tr>
            
              <tr><td>Implications</td><td><p>Very limited data available for CYP2D6 poor metabolizers</p> </td></tr>
            
              <tr><td>Recommendations</td><td><p>Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.</p> </td></tr>
            
              <tr><td>Classification of Recommendation</td><td>No recommendation</td></tr>
            
            </tbody>
          </table>
        
      

      <section>
        
      </section>

      <section>
        <p>For more information see the <a href="https://www.pharmgkb.org/guideline/PA166161954">annotation on PharmGKB</a>.</p>
        
          <p>Citations:</p>
          <ul>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/28002639">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron</a> [PMID:28002639] <em>Clinical pharmacology and therapeutics</em>. 2016.</li>
            
          </ul>
        
        <p><em>Guideline annotation last modified: </em>2016.12.23</p>
      </section>
    </section>
  
    <section class="guideline">
      <h3 id="PA166127636">paroxetine</h3>

      <section>
        <p>The CPIC Dosing Guideline for the selective serotonin reuptake inhibitor paroxetine recommends an alternative drug not predominantly metabolized by CYP2D6 for CYP2D6 ultrarapid metabolizers and for CYP2D6 poor metabolizers. For CYP2D6 poor metabolizers, if paroxetine use is warranted, consider a 50% reduction of recommended starting dose and titrate to response.</p>


        <p>The official guideline can be found on the <a href="https://cpicpgx.org">CPIC website</a>.</p>
      </section>

      

      <section>
        
          <div class="geneCall"><a href="#CYP2D6">CYP2D6: *3/*4</a> (from Astrolabe)</div>
          
        
      </section>

      

      <section>
        
      </section>

      
      
        
      

      

      
        
          <table>
            <thead>
            <tr><th>Type</th><th>Annotation</th></tr>
            </thead>
            <tbody>
            
              <tr><td>Allele Functionality</td><td>CYP2D6:No Function/No Function</td></tr>
            
              <tr><td>Phenotype</td><td>Poor Metabolizer</td></tr>
            
              <tr><td>Activity Score</td><td><p>0</p> </td></tr>
            
              <tr><td>Implications</td><td><p>Greatly reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects.</p> </td></tr>
            
              <tr><td>Recommendations</td><td><p>Select alternative drug not predominantly metabolized by CYP2D6 or if paroxetine use warranted, consider a 50% reduction of recommended starting dose and titrate to response.</p> <p><em>Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.</em></p> </td></tr>
            
              <tr><td>Classification of Recommendation</td><td>Optional</td></tr>
            
            </tbody>
          </table>
        
      

      <section>
        
      </section>

      <section>
        <p>For more information see the <a href="https://www.pharmgkb.org/guideline/PA166127636">annotation on PharmGKB</a>.</p>
        
          <p>Citations:</p>
          <ul>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/25974703">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors</a> [PMID:25974703] <em>Clinical pharmacology and therapeutics</em>. 2015.</li>
            
          </ul>
        
        <p><em>Guideline annotation last modified: </em>2015.05.08</p>
      </section>
    </section>
  
    <section class="guideline">
      <h3 id="PA166110235">peginterferon alfa-2a, peginterferon alfa-2b, ribavirin</h3>

      <section>
        <p>IFNL3 (IL28B) variation (<a href="/variant/PA166155468">rs12979860</a>) is the strongest baseline predictor of response to PEG-interferon-alpha-containing regimens in HCV genotype 1 patients.  Patients with the favorable response genotype (<a href="/variant/PA166155468">rs12979860</a> CC) have increased likelihood of response (higher SVR rate) to PEG-interferon-alpha-containing regimens as compared to patients with unfavorable response genotype (<a href="/variant/PA166155468">rs12979860</a> CT or TT). Consider implications before initiating PEG-IFN alpha and RBV containing regimens.</p>


        <p>The official guideline can be found on the <a href="https://cpicpgx.org">CPIC website</a>.</p>
      </section>

      

      <section>
        
          <div class="geneCall"><a href="#IFNL3">IFNL3: rs12979860C/rs12979860C</a></div>
          
        
      </section>

      

      <section>
        
      </section>

      
      
        
      

      

      
        
          <table>
            <thead>
            <tr><th>Type</th><th>Annotation</th></tr>
            </thead>
            <tbody>
            
              <tr><td>Implications</td><td><p>For patients treated with PEG-IFN alpha and RBV alone, approximately 70% chance for sustained virologic response (SVR, defined by undetectable serum viral RNA 12-24 weeks after the end of treatment) after 48 weeks of treatment. Consider implications before initiating PEG-IFN alpha and RBV containing regimens.</p> <p>For patients treated with protease inhibitor combinations with PEG-IFN alpha and RBV therapy, approximately 90% chance for SVR after 24-48 weeks of treatment. Approximately 80-90% of patients are eligible for shortened therapy (24-28 weeks vs. 48 weeks, with patients receiving boceprevir are eligible for 24-28 weeks instead of the standard 48 weeks if HCV RNA is undetectable by week eight. Patients receiving telaprevir are eligible for 24 weeks of therapy instead of the standard 48 weeks if HCV RNA is undetectable by week four.). Weighs in favor of using PEG-IFN alpha and RBV containing regimens.</p> </td></tr>
            
              <tr><td>Classification of Recommendation</td><td>Strong</td></tr>
            
            </tbody>
          </table>
        
      

      <section>
        
      </section>

      <section>
        <p>For more information see the <a href="https://www.pharmgkb.org/guideline/PA166110235">annotation on PharmGKB</a>.</p>
        
          <p>Citations:</p>
          <ul>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/24096968">Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and peginterferon alpha based regimens</a> [PMID:24096968] <em>Clinical pharmacology and therapeutics</em>. 2013.</li>
            
          </ul>
        
        <p><em>Guideline annotation last modified: </em>2016.02.25</p>
      </section>
    </section>
  
    <section class="guideline">
      <h3 id="PA166122806">phenytoin</h3>

      <section>
        <p>Phenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele (&quot;HLA-B*15:02-positive&quot;) due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype may require reduced doses of phenytoin.</p>


        <p>The official guideline can be found on the <a href="https://cpicpgx.org">CPIC website</a>.</p>
      </section>

      

      <section>
        
          <div class="geneCall"><a href="#CYP2C9">CYP2C9: *1/*1</a></div>
          
        
          <div class="geneCall"><a href="#HLA-B">HLA-B: not called</a></div>
          
        
      </section>

      

      <section>
        
          <div class="alert alert-info">The displayed recommendation for CYP2C9 and phenytoin is ONLY valid for non-carriers of the HLA-B*15:02 high-risk allele. PharmCAT does not interpret HLA carrier status. Phenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele ("HLA-B*15:02-positive") due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). In HLA-B*15:02 carriers, carbamazepine should not be used as an alternative. Alternative medications such as oxcarbazepine, eslicarbazepine acetate, and lamotrigine have some evidence linking SJS/TEN with the HLA-B*15:02 allele, and thus caution should be used in choosing alternatives to phenytoin.</div>
        
      </section>

      
      
        
      

      

      
        
          <table>
            <thead>
            <tr><th>Type</th><th>Annotation</th></tr>
            </thead>
            <tbody>
            
              <tr><td>Allele Functionality</td><td>CYP2C9:Normal Function/Normal Function<br/>HLA-B:Absence/Absence</td></tr>
            
              <tr><td>Phenotype</td><td>CYP2C9 Normal Metabolizer</td></tr>
            
              <tr><td>Implications</td><td><p>Normal phenytoin metabolism.</p> </td></tr>
            
              <tr><td>Recommendations</td><td><p>Initiate therapy with recommended maintenance dose (based on patient’s clinical characteristics).</p> </td></tr>
            
              <tr><td>Classification of Recommendation</td><td>Strong</td></tr>
            
            </tbody>
          </table>
        
      

      <section>
        
      </section>

      <section>
        <p>For more information see the <a href="https://www.pharmgkb.org/guideline/PA166122806">annotation on PharmGKB</a>.</p>
        
          <p>Citations:</p>
          <ul>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/25099164">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing</a> [PMID:25099164] <em>Clinical pharmacology and therapeutics</em>. 2014.</li>
            
          </ul>
        
        <p><em>Guideline annotation last modified: </em>2014.08.05</p>
      </section>
    </section>
  
    <section class="guideline">
      <h3 id="PA166127639">sertraline</h3>

      <section>
        <p>The CPIC Dosing Guideline for the selective serotonin reuptake inhibitor sertraline recommends to consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19 for CYP2C19 poor metabolizers.</p>


        <p>The official guideline can be found on the <a href="https://cpicpgx.org">CPIC website</a>.</p>
      </section>

      

      <section>
        
          <div class="geneCall"><a href="#CYP2C19">CYP2C19: *1/*1</a></div>
          
        
      </section>

      

      <section>
        
      </section>

      
      
        
      

      

      
        
          <table>
            <thead>
            <tr><th>Type</th><th>Annotation</th></tr>
            </thead>
            <tbody>
            
              <tr><td>Allele Functionality</td><td>CYP2C19:Normal Function/Normal Function</td></tr>
            
              <tr><td>Phenotype</td><td>Normal Metabolizer</td></tr>
            
              <tr><td>Implications</td><td><p>Normal metabolism</p> </td></tr>
            
              <tr><td>Recommendations</td><td><p>Initiate therapy with recommended starting dose.</p> </td></tr>
            
              <tr><td>Classification of Recommendation</td><td>Strong</td></tr>
            
            </tbody>
          </table>
        
      

      <section>
        
      </section>

      <section>
        <p>For more information see the <a href="https://www.pharmgkb.org/guideline/PA166127639">annotation on PharmGKB</a>.</p>
        
          <p>Citations:</p>
          <ul>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/25974703">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors</a> [PMID:25974703] <em>Clinical pharmacology and therapeutics</em>. 2015.</li>
            
          </ul>
        
        <p><em>Guideline annotation last modified: </em>2015.05.08</p>
      </section>
    </section>
  
    <section class="guideline">
      <h3 id="PA166105005">simvastatin</h3>

      <section>
        <p>The FDA recommends against 80mg daily simvastatin dosage. In patients with the C allele at SLCO1B1 <a href="/variant/PA166154579">rs4149056</a>, there are modest increases in myopathy risk even at lower simvastatin doses (40mg daily); if optimal efficacy is not achieved with a lower dose, alternate agents should be considered.</p>


        <p>The official guideline can be found on the <a href="https://cpicpgx.org">CPIC website</a>.</p>
      </section>

      

      <section>
        
          <div class="geneCall"><a href="#SLCO1B1">SLCO1B1: *1A/*1A</a></div>
          
            <div class="geneCall"><div><a href="#SLCO1B1">rs4149056T/rs4149056T</a></div></div>
          
        
      </section>

      

      <section>
        
          <div class="alert alert-info">SLCO1B1 star allele nomenclature represents various SNPs alone or in combination. The SLCO1B1 genotype (star nomenclature) will be displayed if determinable with the provided VCF based on the SLCO1B1 star allele definition published by CPIC and recommendations are provided based on the genotype.<br><br>In case no genotype can be determined, recommendations are based on the rs4149056 genotype alone as per guideline. The minor C allele at rs4149056 is contained in SLCO1B1*5 (rs4149056 alone) as well as the *15 and *17 alleles, and is associated with lower plasma clearance of simvastatin. The magnitude of this effect is similar for *5, *15, and *17 alleles. A number of SLCO1B1 alleles (*2, *3, *6, *9, *10, *23, *31) are classified by CPIC as 'possible decreased function' alleles. These alleles are not accounted for in the recommendation based on the rs4149056 genotype. Carriage of additional variants is possible.</div>
        
      </section>

      
      
        
      

      

      
        
          <table>
            <thead>
            <tr><th>Type</th><th>Annotation</th></tr>
            </thead>
            <tbody>
            
              <tr><td>Allele Functionality</td><td>SLCO1B1:Normal Function/Normal Function</td></tr>
            
              <tr><td>Phenotype</td><td>Normal Function</td></tr>
            
              <tr><td>Implications</td><td><p>Normal myopathy risk</p> </td></tr>
            
              <tr><td>Recommendations</td><td><p>Prescribe desired starting dose and adjust doses of simvastatin based on disease-specific guidelines</p> </td></tr>
            
              <tr><td>Classification of Recommendation</td><td>Strong</td></tr>
            
            </tbody>
          </table>
        
      

      <section>
        
          <div class="footnote">In all cases, the potential for drug-drug interaction should be evaluated prior to initiating a prescription. FDA recommends against 80mg of simvastatin (unless already tolerated for 12 months).</div>
        
      </section>

      <section>
        <p>For more information see the <a href="https://www.pharmgkb.org/guideline/PA166105005">annotation on PharmGKB</a>.</p>
        
          <p>Citations:</p>
          <ul>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/24918167">The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update</a> [PMID:24918167] <em>Clinical pharmacology and therapeutics</em>. 2014.</li>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/22617227">The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy</a> [PMID:22617227] <em>Clinical pharmacology and therapeutics</em>. 2012.</li>
            
          </ul>
        
        <p><em>Guideline annotation last modified: </em>2014.06.30</p>
      </section>
    </section>
  
    <section class="guideline">
      <h3 id="PA166124619">tacrolimus</h3>

      <section>
        <p>The CPIC dosing guideline for tacrolimus recommends increasing the starting dose by 1.5 to 2 times the recommended starting dose in patients who are CYP3A5 intermediate or extensive metabolizers, though total starting dose should not exceed 0.3 mg/kg/day. Therapeutic drug monitoring should also be used to guide dose adjustments.</p>


        <p>The official guideline can be found on the <a href="https://cpicpgx.org">CPIC website</a>.</p>
      </section>

      

      <section>
        
          <div class="geneCall"><a href="#CYP3A5">CYP3A5: *1/*1</a></div>
          
        
      </section>

      

      <section>
        
      </section>

      
      
        
      

      

      
        
          <table>
            <thead>
            <tr><th>Type</th><th>Annotation</th></tr>
            </thead>
            <tbody>
            
              <tr><td>Allele Functionality</td><td>CYP3A5:Normal Function/Normal Function</td></tr>
            
              <tr><td>Phenotype</td><td>Normal Metabolizer</td></tr>
            
              <tr><td>Implications</td><td><p>Lower dose-adjusted trough concentrations of tacrolimus and decreased chance of achieving target tacrolimus concentrations.</p> </td></tr>
            
              <tr><td>Recommendations</td><td><p>Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.</p> <p><em>Further dose adjustments or selection of alternative therapy may be necessary because of other clinical factors (e.g., medication interactions, or hepatic function).</em></p> </td></tr>
            
              <tr><td>Classification of Recommendation</td><td>Strong</td></tr>
            
            </tbody>
          </table>
        
      

      <section>
        
      </section>

      <section>
        <p>For more information see the <a href="https://www.pharmgkb.org/guideline/PA166124619">annotation on PharmGKB</a>.</p>
        
          <p>Citations:</p>
          <ul>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/25801146">Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing</a> [PMID:25801146] <em>Clinical pharmacology and therapeutics</em>. 2015.</li>
            
          </ul>
        
        <p><em>Guideline annotation last modified: </em>2015.08.11</p>
      </section>
    </section>
  
    <section class="guideline">
      <h3 id="PA166104965">thioguanine</h3>

      <section>
        <p>Start with reduced doses of thioguanine for patients with one nonfunctional TPMT allele, or drastically reduced doses for patients with malignancy and two nonfunctional alleles; adjust dose based on degree of myelosuppression and disease-specific guidelines. Consider alternative nonthiopurine immunosuppressant therapy for patients with nonmalignant conditions and two nonfunctional alleles.</p>


        <p>The official guideline can be found on the <a href="https://cpicpgx.org">CPIC website</a>.</p>
      </section>

      

      <section>
        
          <div class="geneCall"><a href="#TPMT">TPMT: *1/*1</a></div>
          
        
      </section>

      

      <section>
        
      </section>

      
      
        
      

      

      
        
          <table>
            <thead>
            <tr><th>Type</th><th>Annotation</th></tr>
            </thead>
            <tbody>
            
              <tr><td>Allele Functionality</td><td>TPMT:Normal Function/Normal Function</td></tr>
            
              <tr><td>Phenotype</td><td>Normal Metabolizer</td></tr>
            
              <tr><td>Implications</td><td><p>Lower concentrations of TGN metabolites, but note that TGN after thioguanine are 5-10x higher than TGN after mercaptopurine or azathioprine</p> </td></tr>
            
              <tr><td>Recommendations</td><td><p>Start with normal starting dose. Adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady state after each dose adjustment.</p> </td></tr>
            
              <tr><td>Classification of Recommendation</td><td>Strong</td></tr>
            
            </tbody>
          </table>
        
      

      <section>
        
      </section>

      <section>
        <p>For more information see the <a href="https://www.pharmgkb.org/guideline/PA166104965">annotation on PharmGKB</a>.</p>
        
          <p>Citations:</p>
          <ul>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/23422873">Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update</a> [PMID:23422873] <em>Clinical pharmacology and therapeutics</em>. 2013.</li>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21270794">Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing</a> [PMID:21270794] <em>Clinical pharmacology and therapeutics</em>. 2011.</li>
            
          </ul>
        
        <p><em>Guideline annotation last modified: </em>2016.05.10</p>
      </section>
    </section>
  
    <section class="guideline">
      <h3 id="PA166105001">trimipramine</h3>

      <section>
        <p>Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including trimipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.</p>


        <p>The official guideline can be found on the <a href="https://cpicpgx.org">CPIC website</a>.</p>
      </section>

      

      <section>
        
          <div class="geneCall"><a href="#CYP2D6">CYP2D6: *3/*4</a> (from Astrolabe)</div>
          
        
          <div class="geneCall"><a href="#CYP2C19">CYP2C19: *1/*1</a></div>
          
        
      </section>

      

      <section>
        
      </section>

      
      
        
      

      

      
        
          <table>
            <thead>
            <tr><th>Type</th><th>Annotation</th></tr>
            </thead>
            <tbody>
            
              <tr><td>Allele Functionality</td><td>CYP2C19:Normal Function/Normal Function<br/>CYP2D6:No Function/No Function</td></tr>
            
              <tr><td>Phenotype</td><td>CYP2D6 Poor Metabolizer CYP2C19 Normal Metabolizer</td></tr>
            
              <tr><td>Implications</td><td><p><strong>For CYP2D6:</strong></p> <p>Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.</p> <p><strong>For CYP2C19:</strong></p> <p>Normal metabolism of tertiary amines.</p> </td></tr>
            
              <tr><td>Recommendations</td><td><p>The dosing recommendations are based on studies focusing on amitriptyline. Because tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply these guidelines to other tertiary amines including clomipramine, doxepin, imipramine and trimipramine.</p> <p><strong>Avoid TCA use. If TCAs are warranted, consider 50% reduction of recommended starting dose.</strong></p> <p><em>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended. Patients may receive an initial low dose of TCAs, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression.</em></p> </td></tr>
            
              <tr><td>Classification of Recommendation</td><td>Optional</td></tr>
            
            </tbody>
          </table>
        
      

      <section>
        
          <div class="footnote">Classification of recommendation might differ based on the availabilty of CYP2D6 or CYP2C19 genotypes only or a combination of CYP2D6 and CYP2C19 genotypes; see full guideline at cpicpgx.org.</div>
        
      </section>

      <section>
        <p>For more information see the <a href="https://www.pharmgkb.org/guideline/PA166105001">annotation on PharmGKB</a>.</p>
        
          <p>Citations:</p>
          <ul>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/27997040">Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update</a> [PMID:27997040] <em>Clinical pharmacology and therapeutics</em>. 2016.</li>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/23486447">Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants</a> [PMID:23486447] <em>Clinical pharmacology and therapeutics</em>. 2013.</li>
            
          </ul>
        
        <p><em>Guideline annotation last modified: </em>2016.12.14</p>
      </section>
    </section>
  
    <section class="guideline">
      <h3 id="PA166161955">tropisetron</h3>

      <section>
        <p>The CPIC dosing guideline for tropisetron recommends selecting an alternate drug for CYP2D6 ultrarapid metabolizers.  It is recommended that the alternate drug not be predominantly metabolized by CYP2D6 (eg. granisetron).</p>


        <p>The official guideline can be found on the <a href="https://cpicpgx.org">CPIC website</a>.</p>
      </section>

      

      <section>
        
          <div class="geneCall"><a href="#CYP2D6">CYP2D6: *3/*4</a> (from Astrolabe)</div>
          
        
      </section>

      

      <section>
        
      </section>

      
      
        
      

      

      
        
          <table>
            <thead>
            <tr><th>Type</th><th>Annotation</th></tr>
            </thead>
            <tbody>
            
              <tr><td>Allele Functionality</td><td>CYP2D6:No Function/No Function</td></tr>
            
              <tr><td>Phenotype</td><td>Poor Metabolizer</td></tr>
            
              <tr><td>Activity Score</td><td><p>0</p> </td></tr>
            
              <tr><td>Implications</td><td><p>Very limited data available for CYP2D6 poor metabolizers</p> </td></tr>
            
              <tr><td>Recommendations</td><td><p>Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.</p> </td></tr>
            
              <tr><td>Classification of Recommendation</td><td>No recommendation</td></tr>
            
            </tbody>
          </table>
        
      

      <section>
        
      </section>

      <section>
        <p>For more information see the <a href="https://www.pharmgkb.org/guideline/PA166161955">annotation on PharmGKB</a>.</p>
        
          <p>Citations:</p>
          <ul>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/28002639">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron</a> [PMID:28002639] <em>Clinical pharmacology and therapeutics</em>. 2016.</li>
            
          </ul>
        
        <p><em>Guideline annotation last modified: </em>2016.12.23</p>
      </section>
    </section>
  
    <section class="guideline">
      <h3 id="PA166161537">voriconazole</h3>

      <section>
        <p>The CPIC dosing guideline for voriconazole recommends selecting an alternative agent that is not dependent on CYP2C19 metabolism in adults who are CYP2C19 ultrarapid metabolizers, rapid metabolizers or poor metabolizers. In pediatric patients, an alternative agent should be used in patients who are ultrarapid metabolizers or poor metabolizers. In pediatric rapid metabolizers, therapy should be initiated at recommended standard case dosing, then therapeutic dosing monitoring should be used to titrate dose to therapeutic trough concentrations.</p>


        <p>The official guideline can be found on the <a href="https://cpicpgx.org">CPIC website</a>.</p>
      </section>

      

      <section>
        
          <div class="geneCall"><a href="#CYP2C19">CYP2C19: *1/*1</a></div>
          
        
      </section>

      

      <section>
        
      </section>

      
      
        
      

      

      
        
          <table>
            <thead>
            <tr><th>Type</th><th>Annotation</th></tr>
            </thead>
            <tbody>
            
              <tr><td>Allele Functionality</td><td>CYP2C19:Normal Function/Normal Function</td></tr>
            
              <tr><td>Phenotype</td><td>Normal Metabolizer</td></tr>
            
              <tr><td>Implications</td><td><p>Normal voriconazole metabolism</p> </td></tr>
            
              <tr><td>Recommendations</td><td><p>For pediatric or adult patients: initiate therapy with recommended standard of care dosing.</p> <p><em>Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, TDM, and comorbidities.</em></p> </td></tr>
            
              <tr><td>Classification of Recommendation</td><td>Strong</td></tr>
            
            </tbody>
          </table>
        
      

      <section>
        
      </section>

      <section>
        <p>For more information see the <a href="https://www.pharmgkb.org/guideline/PA166161537">annotation on PharmGKB</a>.</p>
        
          <p>Citations:</p>
          <ul>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/27981572">Clinical Pharmacogenetics Implementation Consortium (CPIC®) Guideline for CYP2C19 and Voriconazole Therapy</a> [PMID:27981572] <em>Clinical pharmacology and therapeutics</em>. 2016.</li>
            
          </ul>
        
        <p><em>Guideline annotation last modified: </em>2016.12.02</p>
      </section>
    </section>
  
    <section class="guideline">
      <h3 id="PA166104949">warfarin</h3>

      <section>
        <p>The updated guideline for pharmacogenetics-guided warfarin dosing is published by the <em>Clinical Pharmacogenetics Implementation Consortium</em>.  The  recommendations for dosing are for adult and pediatric patients that are specific to continental ancestry, and are based on genotypes from <em>CYP2C9</em>, <em>VKORC1</em>, <em>CYP4F2</em>, and rs12777823.</p>


        <p>The official guideline can be found on the <a href="https://cpicpgx.org">CPIC website</a>.</p>
      </section>

      

      <section>
        
          <div class="geneCall"><a href="#VKORC1">VKORC1: -1639A/-1639A</a></div>
          
        
          <div class="geneCall"><a href="#CYP2C9">CYP2C9: *1/*1</a></div>
          
        
          <div class="geneCall"><a href="#CYP4F2">CYP4F2: *1/*1</a></div>
          
        
          <div class="geneCall"><a href="#rs12777823">rs12777823: missing</a></div>
          
        
      </section>

      

      <section>
        
          <div class="alert alert-info">Please follow the flow chart in figure 2 of the <a href="https://www.pharmgkb.org/guideline/PA166104949">CPIC warfarin guideline</a> to determine the appropriate dosing recommendation.</div>
        
      </section>

      
      
        
      

      
        <div class="image"><img src="http://s3.pgkb.org/attachment/CPIC_warfarin_2017_Fig_2.png" alt="Figure 2 from the CPIC guideline for warfarin"/></div>
      

      
        
      

      <section>
        
          <div class="footnote">The CPIC warfarin guideline only considers a single SNV in VKORC1 (rs9923231), which is found in the highest frequency in Caucasians and extremely low frequency in those of African descent. While other functional variants in VKORC1 have been observed in much higher frequencies in some populations, there are currently no CPIC recommendations for how to use these other variants in warfarin dosing. An alternate name for rs9923231 is -1639G&gt;A (note that VKORC1 is on the negative chromosomal strand, so displayed alleles are complemented). </div>
        
      </section>

      <section>
        <p>For more information see the <a href="https://www.pharmgkb.org/guideline/PA166104949">annotation on PharmGKB</a>.</p>
        
          <p>Citations:</p>
          <ul>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/28198005">Clinical pharmacogenetics implementation consortium (cpic) guideline for pharmacogenetics-guided warfarin dosing: 2017 update</a> [PMID:28198005] <em>Clinical pharmacology and therapeutics</em>. 2017.</li>
            
              <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/21900891">Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing</a> [PMID:21900891] <em>Clinical pharmacology and therapeutics</em>. 2011.</li>
            
          </ul>
        
        <p><em>Guideline annotation last modified: </em>2017.02.08</p>
      </section>
    </section>
  
</section>

<section id="genes">
  <h2>Allele Matching Details</h2>

  <div>
  <ol>
  
    <li><a href="#CFTR">CFTR allele match data</a></li>
  
    <li><a href="#CYP2C19">CYP2C19 allele match data</a></li>
  
    <li><a href="#CYP2C9">CYP2C9 allele match data</a></li>
  
    <li><a href="#CYP2D6">CYP2D6 allele match data</a></li>
  
    <li><a href="#CYP3A5">CYP3A5 allele match data</a></li>
  
    <li><a href="#CYP4F2">CYP4F2 allele match data</a></li>
  
    <li><a href="#DPYD">DPYD allele match data</a></li>
  
    <li><a href="#IFNL3">IFNL3 allele match data</a></li>
  
    <li><a href="#SLCO1B1">SLCO1B1 allele match data</a></li>
  
    <li><a href="#TPMT">TPMT allele match data</a></li>
  
    <li><a href="#UGT1A1">UGT1A1 allele match data</a></li>
  
    <li><a href="#VKORC1">VKORC1 allele match data</a></li>
  
  </ol>
  </div>

  
    <section class="gene">
      <h3 id="CFTR">CFTR allele match data</h3>

      <h4>Genotype matched</h4>
      <ul>
        
          <li>No CPIC variants found</li>
        
      </ul>

      <h4>Phasing status</h4><div>Phased</div>

      

      

      

      

      

      
        <h4>Calls at Positions</h4>
        <table>
          <thead>
          <tr>
            <th>Position</th>
            <th>RSID</th>
            <th>Call</th>
            <th>Reference</th>
            <th>Related Alleles</th>
          </tr>
          </thead>
          <tbody>
          
            <tr>
              <td id="117509035">117509035</td>
              <td id="rs397508256">rs397508256</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                E56K 
              </td>
            </tr>
          
            <tr>
              <td id="117509069">117509069</td>
              <td id="rs368505753">rs368505753</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                P67L 
              </td>
            </tr>
          
            <tr>
              <td id="117509089">117509089</td>
              <td id="rs115545701">rs115545701</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                R74W 
              </td>
            </tr>
          
            <tr>
              <td id="117509123">117509123</td>
              <td id="rs75961395">rs75961395</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                G85E 
              </td>
            </tr>
          
            <tr>
              <td id="117530953">117530953</td>
              <td id="rs113993958">rs113993958</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                D110H 
              </td>
            </tr>
          
            <tr>
              <td id="117530955">117530955</td>
              <td id="rs397508537">rs397508537</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                D110E 
              </td>
            </tr>
          
            <tr>
              <td id="117530974">117530974</td>
              <td id="rs77834169">rs77834169</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                R117C 
              </td>
            </tr>
          
            <tr>
              <td id="117530975">117530975</td>
              <td id="rs78655421">rs78655421</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                R117H 
              </td>
            </tr>
          
            <tr>
              <td id="117531115">117531115</td>
              <td id="rs78756941">rs78756941</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                621+1G-&gt;T 
              </td>
            </tr>
          
            <tr>
              <td id="117534318">117534318</td>
              <td id="rs80282562">rs80282562</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                G178R 
              </td>
            </tr>
          
            <tr>
              <td id="117534363">117534363</td>
              <td id="rs397508759">rs397508759</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                E193K 
              </td>
            </tr>
          
            <tr>
              <td id="117534366">117534366</td>
              <td id="rs77188391">rs77188391</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                711+1G-&gt;T 
              </td>
            </tr>
          
            <tr>
              <td id="117535285">117535285</td>
              <td id="rs121908752">rs121908752</td>
              
              
                <td class="">T|T</td>
              
              <td>
                T
              </td>
              <td>
                L206W 
              </td>
            </tr>
          
            <tr>
              <td id="117540230">117540230</td>
              <td id="rs121909011">rs121909011</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                R334W 
              </td>
            </tr>
          
            <tr>
              <td id="117540270">117540270</td>
              <td id="rs77932196">rs77932196</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                R347H R347P 
              </td>
            </tr>
          
            <tr>
              <td id="117540285">117540285</td>
              <td id="rs121908753">rs121908753</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                R352Q 
              </td>
            </tr>
          
            <tr>
              <td id="117548795">117548795</td>
              <td id="rs74551128">rs74551128</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                A455E 
              </td>
            </tr>
          
            <tr>
              <td id="117559590">117559590</td>
              <td id="rs121908745">rs121908745</td>
              
              
                <td class="">ATC|ATC</td>
              
              <td>
                ATC
              </td>
              <td>
                I507 
              </td>
            </tr>
          
            <tr>
              <td id="117559592">117559592</td>
              <td id="rs113993960">rs113993960</td>
              
              
                <td class="">CTT|CTT</td>
              
              <td>
                CTT
              </td>
              <td>
                F508del(CTT) 
              </td>
            </tr>
          
            <tr>
              <td id="117587738">117587738</td>
              <td id="rs76713772">rs76713772</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                1717-1G-&gt;A 
              </td>
            </tr>
          
            <tr>
              <td id="117587778">117587778</td>
              <td id="rs113993959">rs113993959</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                G542X 
              </td>
            </tr>
          
            <tr>
              <td id="117587799">117587799</td>
              <td id="rs121908757">rs121908757</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                S549R(A&gt;C) 
              </td>
            </tr>
          
            <tr>
              <td id="117587800">117587800</td>
              <td id="rs121908755">rs121908755</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                S549N 
              </td>
            </tr>
          
            <tr>
              <td id="117587801">117587801</td>
              <td id="rs121909005">rs121909005</td>
              
              
                <td class="">T|T</td>
              
              <td>
                T
              </td>
              <td>
                S549R(T&gt;G) 
              </td>
            </tr>
          
            <tr>
              <td id="117587805">117587805</td>
              <td id="rs121909013">rs121909013</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                G551S 
              </td>
            </tr>
          
            <tr>
              <td id="117587806">117587806</td>
              <td id="rs75527207">rs75527207</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                G551D 
              </td>
            </tr>
          
            <tr>
              <td id="117587811">117587811</td>
              <td id="rs74597325">rs74597325</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                R553X 
              </td>
            </tr>
          
            <tr>
              <td id="117587833">117587833</td>
              <td id="rs80055610">rs80055610</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                R560T 
              </td>
            </tr>
          
            <tr>
              <td id="117590409">117590409</td>
              <td id="rs397508288">rs397508288</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                D579G 
              </td>
            </tr>
          
            <tr>
              <td id="117590440">117590440</td>
              <td id="rs121908748">rs121908748</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                1898+1G-&gt;A 
              </td>
            </tr>
          
            <tr>
              <td id="117592219">117592219</td>
              <td id="rs121908746">rs121908746</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                2184delA 
              </td>
            </tr>
          
            <tr>
              <td id="117602868">117602868</td>
              <td id="rs80224560">rs80224560</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                2789+5G-&gt;A 
              </td>
            </tr>
          
            <tr>
              <td id="117603708">117603708</td>
              <td id="rs397508442">rs397508442</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                S945L 
              </td>
            </tr>
          
            <tr>
              <td id="117606695">117606695</td>
              <td id="rs141033578">rs141033578</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                S977F 
              </td>
            </tr>
          
            <tr>
              <td id="117606754">117606754</td>
              <td id="rs75096551">rs75096551</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                3120+1G-&gt;A 
              </td>
            </tr>
          
            <tr>
              <td id="117611595">117611595</td>
              <td id="rs150212784">rs150212784</td>
              
              
                <td class="">T|T</td>
              
              <td>
                T
              </td>
              <td>
                F1052V 
              </td>
            </tr>
          
            <tr>
              <td id="117611620">117611620</td>
              <td id="rs397508513">rs397508513</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                K1060T 
              </td>
            </tr>
          
            <tr>
              <td id="117611640">117611640</td>
              <td id="rs121909020">rs121909020</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                A1067T 
              </td>
            </tr>
          
            <tr>
              <td id="117611646">117611646</td>
              <td id="rs200321110">rs200321110</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                G1069R 
              </td>
            </tr>
          
            <tr>
              <td id="117611649">117611649</td>
              <td id="rs202179988">rs202179988</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                R1070W 
              </td>
            </tr>
          
            <tr>
              <td id="117611650">117611650</td>
              <td id="rs78769542">rs78769542</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                R1070Q 
              </td>
            </tr>
          
            <tr>
              <td id="117611663">117611663</td>
              <td id="rs186045772">rs186045772</td>
              
              
                <td class="">T|T</td>
              
              <td>
                T
              </td>
              <td>
                F1074L 
              </td>
            </tr>
          
            <tr>
              <td id="117614699">117614699</td>
              <td id="rs75541969">rs75541969</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                D1152H 
              </td>
            </tr>
          
            <tr>
              <td id="117627537">117627537</td>
              <td id="rs74767530">rs74767530</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                R1162X 
              </td>
            </tr>
          
            <tr>
              <td id="117627581">117627581</td>
              <td id="rs121908747">rs121908747</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                3659delC 
              </td>
            </tr>
          
            <tr>
              <td id="117639961">117639961</td>
              <td id="rs75039782">rs75039782</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                3849+10kbC- &gt;T 
              </td>
            </tr>
          
            <tr>
              <td id="117642451">117642451</td>
              <td id="rs267606723">rs267606723</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                G1244E 
              </td>
            </tr>
          
            <tr>
              <td id="117642472">117642472</td>
              <td id="rs74503330">rs74503330</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                S1251N 
              </td>
            </tr>
          
            <tr>
              <td id="117642483">117642483</td>
              <td id="rs121909041">rs121909041</td>
              
              
                <td class="">T|T</td>
              
              <td>
                T
              </td>
              <td>
                S1255P 
              </td>
            </tr>
          
            <tr>
              <td id="117642528">117642528</td>
              <td id="rs11971167">rs11971167</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                D1270N 
              </td>
            </tr>
          
            <tr>
              <td id="117642566">117642566</td>
              <td id="rs77010898">rs77010898</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                W1282X 
              </td>
            </tr>
          
            <tr>
              <td id="117652877">117652877</td>
              <td id="rs80034486">rs80034486</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                N1303K 
              </td>
            </tr>
          
            <tr>
              <td id="117664770">117664770</td>
              <td id="rs193922525">rs193922525</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                G1349D 
              </td>
            </tr>
          
          </tbody>
        </table>
      

      
    </section>
  
    <section class="gene">
      <h3 id="CYP2C19">CYP2C19 allele match data</h3>

      <h4>Genotype matched</h4>
      <ul>
        
          <li>*1/*1</li>
        
      </ul>

      <h4>Phasing status</h4><div>Phased</div>

      

      

      

      

      

      
        <h4>Calls at Positions</h4>
        <table>
          <thead>
          <tr>
            <th>Position</th>
            <th>RSID</th>
            <th>Call</th>
            <th>Reference</th>
            <th>Related Alleles</th>
          </tr>
          </thead>
          <tbody>
          
            <tr>
              <td id="94761665">94761665</td>
              <td id="rs7902257">rs7902257</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *27 
              </td>
            </tr>
          
            <tr>
              <td id="94761900">94761900</td>
              <td id="rs12248560">rs12248560</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *4B *17 
              </td>
            </tr>
          
            <tr>
              <td id="94762706">94762706</td>
              <td id="rs28399504">rs28399504</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *4A *4B 
              </td>
            </tr>
          
            <tr>
              <td id="94762712">94762712</td>
              <td id="rs367543002">rs367543002</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *34 
              </td>
            </tr>
          
            <tr>
              <td id="94762715">94762715</td>
              <td id="rs367543003">rs367543003</td>
              
              
                <td class="">T|T</td>
              
              <td>
                T
              </td>
              <td>
                *34 
              </td>
            </tr>
          
            <tr>
              <td id="94762755">94762755</td>
              <td id="rs55752064">rs55752064</td>
              
              
                <td class="">T|T</td>
              
              <td>
                T
              </td>
              <td>
                *14 
              </td>
            </tr>
          
            <tr>
              <td id="94762760">94762760</td>
              <td id="rs17882687">rs17882687</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *15 *28 
              </td>
            </tr>
          
            <tr>
              <td id="94762788">94762788</td>
              <td id=""></td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *29 
              </td>
            </tr>
          
            <tr>
              <td id="94762856">94762856</td>
              <td id=""></td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *19 
              </td>
            </tr>
          
            <tr>
              <td id="94775106">94775106</td>
              <td id="rs145328984">rs145328984</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *30 
              </td>
            </tr>
          
            <tr>
              <td id="94775121">94775121</td>
              <td id=""></td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *31 
              </td>
            </tr>
          
            <tr>
              <td id="94775160">94775160</td>
              <td id="rs118203756">rs118203756</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *23 
              </td>
            </tr>
          
            <tr>
              <td id="94775185">94775185</td>
              <td id=""></td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *32 
              </td>
            </tr>
          
            <tr>
              <td id="94775367">94775367</td>
              <td id="rs12769205">rs12769205</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *2 *35 
              </td>
            </tr>
          
            <tr>
              <td id="94775416">94775416</td>
              <td id="rs41291556">rs41291556</td>
              
              
                <td class="">T|T</td>
              
              <td>
                T
              </td>
              <td>
                *8 
              </td>
            </tr>
          
            <tr>
              <td id="94775453">94775453</td>
              <td id="rs72552267">rs72552267</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *6 
              </td>
            </tr>
          
            <tr>
              <td id="94775489">94775489</td>
              <td id="rs17884712">rs17884712</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *9 
              </td>
            </tr>
          
            <tr>
              <td id="94775507">94775507</td>
              <td id="rs58973490">rs58973490</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *11 
              </td>
            </tr>
          
            <tr>
              <td id="94780574">94780574</td>
              <td id="rs140278421">rs140278421</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *22 
              </td>
            </tr>
          
            <tr>
              <td id="94780579">94780579</td>
              <td id="rs370803989">rs370803989</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *33 
              </td>
            </tr>
          
            <tr>
              <td id="94780653">94780653</td>
              <td id="rs4986893">rs4986893</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *3 
              </td>
            </tr>
          
            <tr>
              <td id="94781858">94781858</td>
              <td id="rs6413438">rs6413438</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *10 
              </td>
            </tr>
          
            <tr>
              <td id="94781859">94781859</td>
              <td id="rs4244285">rs4244285</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *2 
              </td>
            </tr>
          
            <tr>
              <td id="94781944">94781944</td>
              <td id=""></td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *26 
              </td>
            </tr>
          
            <tr>
              <td id="94781999">94781999</td>
              <td id="rs72558186">rs72558186</td>
              
              
                <td class="">T|T</td>
              
              <td>
                T
              </td>
              <td>
                *7 
              </td>
            </tr>
          
            <tr>
              <td id="94842861">94842861</td>
              <td id="rs138142612">rs138142612</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *18 
              </td>
            </tr>
          
            <tr>
              <td id="94842879">94842879</td>
              <td id="rs118203757">rs118203757</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *24 
              </td>
            </tr>
          
            <tr>
              <td id="94842995">94842995</td>
              <td id="rs113934938">rs113934938</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *28 
              </td>
            </tr>
          
            <tr>
              <td id="94849964">94849964</td>
              <td id="rs377184510">rs377184510</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *24 
              </td>
            </tr>
          
            <tr>
              <td id="94849995">94849995</td>
              <td id="rs17879685">rs17879685</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *13 
              </td>
            </tr>
          
            <tr>
              <td id="94852738">94852738</td>
              <td id="rs56337013">rs56337013</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *5 
              </td>
            </tr>
          
            <tr>
              <td id="94852765">94852765</td>
              <td id="rs192154563">rs192154563</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *16 
              </td>
            </tr>
          
            <tr>
              <td id="94852785">94852785</td>
              <td id="rs118203759">rs118203759</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *25 
              </td>
            </tr>
          
            <tr>
              <td id="94852914">94852914</td>
              <td id="rs55640102">rs55640102</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *12 
              </td>
            </tr>
          
          </tbody>
        </table>
      

      
    </section>
  
    <section class="gene">
      <h3 id="CYP2C9">CYP2C9 allele match data</h3>

      <h4>Genotype matched</h4>
      <ul>
        
          <li>*1/*1</li>
        
      </ul>

      <h4>Phasing status</h4><div>Phased</div>

      

      

      

      

      

      
        <h4>Calls at Positions</h4>
        <table>
          <thead>
          <tr>
            <th>Position</th>
            <th>RSID</th>
            <th>Call</th>
            <th>Reference</th>
            <th>Related Alleles</th>
          </tr>
          </thead>
          <tbody>
          
            <tr>
              <td id="94938683">94938683</td>
              <td id="rs114071557">rs114071557</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *36 
              </td>
            </tr>
          
            <tr>
              <td id="94938737">94938737</td>
              <td id="rs67807361">rs67807361</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *7 
              </td>
            </tr>
          
            <tr>
              <td id="94938771">94938771</td>
              <td id="rs142240658">rs142240658</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *21 
              </td>
            </tr>
          
            <tr>
              <td id="94938803">94938803</td>
              <td id=""></td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *22 
              </td>
            </tr>
          
            <tr>
              <td id="94938828">94938828</td>
              <td id="rs564813580">rs564813580</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *37 
              </td>
            </tr>
          
            <tr>
              <td id="94941897">94941897</td>
              <td id="rs371055887">rs371055887</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *20 
              </td>
            </tr>
          
            <tr>
              <td id="94941915">94941915</td>
              <td id=""></td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *23 
              </td>
            </tr>
          
            <tr>
              <td id="94941958">94941958</td>
              <td id="rs72558187">rs72558187</td>
              
              
                <td class="">T|T</td>
              
              <td>
                T
              </td>
              <td>
                *13 
              </td>
            </tr>
          
            <tr>
              <td id="94941976">94941976</td>
              <td id=""></td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *38 
              </td>
            </tr>
          
            <tr>
              <td id="94941982">94941982</td>
              <td id="rs762239445">rs762239445</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *39 
              </td>
            </tr>
          
            <tr>
              <td id="94942018">94942018</td>
              <td id=""></td>
              
              
                <td class="">T|T</td>
              
              <td>
                T
              </td>
              <td>
                *40 
              </td>
            </tr>
          
            <tr>
              <td id="94942213">94942213</td>
              <td id=""></td>
              
              
                <td class="">AGAAATGGAA|AGAAATGGAA</td>
              
              <td>
                AGAAATGGAA
              </td>
              <td>
                *25 
              </td>
            </tr>
          
            <tr>
              <td id="94942216">94942216</td>
              <td id=""></td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *41 
              </td>
            </tr>
          
            <tr>
              <td id="94942230">94942230</td>
              <td id="rs767576260">rs767576260</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *43 
              </td>
            </tr>
          
            <tr>
              <td id="94942231">94942231</td>
              <td id="rs12414460">rs12414460</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *42 
              </td>
            </tr>
          
            <tr>
              <td id="94942234">94942234</td>
              <td id="rs72558189">rs72558189</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *14 *35 
              </td>
            </tr>
          
            <tr>
              <td id="94942249">94942249</td>
              <td id="rs200965026">rs200965026</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *26 *44 
              </td>
            </tr>
          
            <tr>
              <td id="94942254">94942254</td>
              <td id="rs199523631">rs199523631</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *45 
              </td>
            </tr>
          
            <tr>
              <td id="94942255">94942255</td>
              <td id="rs200183364">rs200183364</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *33 
              </td>
            </tr>
          
            <tr>
              <td id="94942290">94942290</td>
              <td id="rs1799853">rs1799853</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *2 *35 
              </td>
            </tr>
          
            <tr>
              <td id="94942305">94942305</td>
              <td id="rs754487195">rs754487195</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *46 
              </td>
            </tr>
          
            <tr>
              <td id="94942309">94942309</td>
              <td id="rs7900194">rs7900194</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *8 *27 
              </td>
            </tr>
          
            <tr>
              <td id="94947782">94947782</td>
              <td id="rs72558190">rs72558190</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *15 
              </td>
            </tr>
          
            <tr>
              <td id="94947785">94947785</td>
              <td id="rs774550549">rs774550549</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *47 
              </td>
            </tr>
          
            <tr>
              <td id="94947907">94947907</td>
              <td id=""></td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *57 
              </td>
            </tr>
          
            <tr>
              <td id="94947917">94947917</td>
              <td id=""></td>
              
              
                <td class="">T|T</td>
              
              <td>
                T
              </td>
              <td>
                *48 
              </td>
            </tr>
          
            <tr>
              <td id="94947938">94947938</td>
              <td id=""></td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *28 
              </td>
            </tr>
          
            <tr>
              <td id="94949129">94949129</td>
              <td id=""></td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *49 
              </td>
            </tr>
          
            <tr>
              <td id="94949144">94949144</td>
              <td id=""></td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *50 
              </td>
            </tr>
          
            <tr>
              <td id="94949217">94949217</td>
              <td id="rs2256871">rs2256871</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *9 
              </td>
            </tr>
          
            <tr>
              <td id="94949280">94949280</td>
              <td id="rs9332130">rs9332130</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *10 
              </td>
            </tr>
          
            <tr>
              <td id="94949282">94949282</td>
              <td id="rs9332131">rs9332131</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *6 
              </td>
            </tr>
          
            <tr>
              <td id="94972119">94972119</td>
              <td id="rs182132442">rs182132442</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *29 
              </td>
            </tr>
          
            <tr>
              <td id="94972134">94972134</td>
              <td id=""></td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *51 
              </td>
            </tr>
          
            <tr>
              <td id="94972179">94972179</td>
              <td id="rs72558192">rs72558192</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *16 
              </td>
            </tr>
          
            <tr>
              <td id="94972180">94972180</td>
              <td id=""></td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *52 
              </td>
            </tr>
          
            <tr>
              <td id="94972233">94972233</td>
              <td id=""></td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *53 
              </td>
            </tr>
          
            <tr>
              <td id="94981201">94981201</td>
              <td id="rs57505750">rs57505750</td>
              
              
                <td class="">T|T</td>
              
              <td>
                T
              </td>
              <td>
                *31 
              </td>
            </tr>
          
            <tr>
              <td id="94981224">94981224</td>
              <td id="rs28371685">rs28371685</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *11 
              </td>
            </tr>
          
            <tr>
              <td id="94981225">94981225</td>
              <td id="rs367826293">rs367826293</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *34 
              </td>
            </tr>
          
            <tr>
              <td id="94981250">94981250</td>
              <td id="rs750820937">rs750820937</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *54 
              </td>
            </tr>
          
            <tr>
              <td id="94981281">94981281</td>
              <td id="rs749060448">rs749060448</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *24 
              </td>
            </tr>
          
            <tr>
              <td id="94981296">94981296</td>
              <td id="rs1057910">rs1057910</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *3 *18 
              </td>
            </tr>
          
            <tr>
              <td id="94981297">94981297</td>
              <td id="rs56165452">rs56165452</td>
              
              
                <td class="">T|T</td>
              
              <td>
                T
              </td>
              <td>
                *4 
              </td>
            </tr>
          
            <tr>
              <td id="94981301">94981301</td>
              <td id="rs28371686">rs28371686</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *5 
              </td>
            </tr>
          
            <tr>
              <td id="94981302">94981302</td>
              <td id=""></td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *55 
              </td>
            </tr>
          
            <tr>
              <td id="94981365">94981365</td>
              <td id=""></td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *17 
              </td>
            </tr>
          
            <tr>
              <td id="94986042">94986042</td>
              <td id="rs764211126">rs764211126</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *56 
              </td>
            </tr>
          
            <tr>
              <td id="94986073">94986073</td>
              <td id="rs72558193">rs72558193</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *18 
              </td>
            </tr>
          
            <tr>
              <td id="94988917">94988917</td>
              <td id="rs769942899">rs769942899</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *19 
              </td>
            </tr>
          
            <tr>
              <td id="94988984">94988984</td>
              <td id="rs781583846">rs781583846</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *30 
              </td>
            </tr>
          
            <tr>
              <td id="94989020">94989020</td>
              <td id="rs9332239">rs9332239</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *12 
              </td>
            </tr>
          
            <tr>
              <td id="94989023">94989023</td>
              <td id=""></td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *32 
              </td>
            </tr>
          
          </tbody>
        </table>
      

      
        <h4>Other Positions of Interest</h4>
        
        <table>
          <thead>
          <tr>
            <th>Position</th>
            <th>RSID</th>
            <th>Call</th>
          </tr>
          </thead>
          <tbody>
          
            <tr>
              <td id="94645745">94645745</td>
              <td id="rs12777823">rs12777823</td>
              
              
                <td class="">G/A</td>
              
            </tr>
          
          </tbody>
        </table>
      
    </section>
  
    <section class="gene">
      <h3 id="CYP2D6">CYP2D6 allele match data</h3>

      <h4>Genotype matched</h4>
      <ul>
        
          <li>*3/*4</li>
        
      </ul>

      <h4>Phasing status</h4><div>Unavailable for Astrolabe calls</div>

      

      
        <div class="alert alert-info">
          The call for CYP2D6 comes from Astrolabe data which does not supply position-level detail. For specific
          disclaimers and limitations, see Astrolabe specification.
        </div>
      

      
        <div class="alert alert-info">No variant data available.</div>
      

      

      
        <div class="alert alert-warning">CYP2D6 genotypes are called by a separate algorithm from other genes in the PharmCAT report.  Please refer to <a href="https://github.com/PharmGKB/PharmCAT/wiki/Determining-Alleles">the PharmCAT wiki</a> for more information.</div>
      

      

      
    </section>
  
    <section class="gene">
      <h3 id="CYP3A5">CYP3A5 allele match data</h3>

      <h4>Genotype matched</h4>
      <ul>
        
          <li>*1/*1</li>
        
      </ul>

      <h4>Phasing status</h4><div>Phased</div>

      

      

      

      

      
        <div class="alert alert-warning">CYP3A5 is known to have one or more functional variants in intronic regions.  Since intronic variants are important for CYP3A5 genotype assignment, further testing may be warranted for exome data.</div>
      

      
        <h4>Calls at Positions</h4>
        <table>
          <thead>
          <tr>
            <th>Position</th>
            <th>RSID</th>
            <th>Call</th>
            <th>Reference</th>
            <th>Related Alleles</th>
          </tr>
          </thead>
          <tbody>
          
            <tr>
              <td id="99652613">99652613</td>
              <td id="rs28365083">rs28365083</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *2 
              </td>
            </tr>
          
            <tr>
              <td id="99652770">99652770</td>
              <td id="rs41303343">rs41303343</td>
              
              
                <td class="">del|del</td>
              
              <td>
                del
              </td>
              <td>
                *7 
              </td>
            </tr>
          
            <tr>
              <td id="99660516">99660516</td>
              <td id="rs28383479">rs28383479</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *3 *9 
              </td>
            </tr>
          
            <tr>
              <td id="99665212">99665212</td>
              <td id="rs10264272">rs10264272</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *6 
              </td>
            </tr>
          
            <tr>
              <td id="99665237">99665237</td>
              <td id="rs56411402">rs56411402</td>
              
              
                <td class="">T|T</td>
              
              <td>
                T
              </td>
              <td>
                *4 
              </td>
            </tr>
          
            <tr>
              <td id="99666950">99666950</td>
              <td id="rs55965422">rs55965422</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *5 
              </td>
            </tr>
          
            <tr>
              <td id="99672916">99672916</td>
              <td id="rs776746">rs776746</td>
              
              
                <td class="">T|T</td>
              
              <td>
                T
              </td>
              <td>
                *3 
              </td>
            </tr>
          
            <tr>
              <td id="99676198">99676198</td>
              <td id="rs55817950">rs55817950</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *8 
              </td>
            </tr>
          
          </tbody>
        </table>
      

      
    </section>
  
    <section class="gene">
      <h3 id="CYP4F2">CYP4F2 allele match data</h3>

      <h4>Genotype matched</h4>
      <ul>
        
          <li>*1/*1</li>
        
      </ul>

      <h4>Phasing status</h4><div>Phased</div>

      

      

      

      

      

      
        <h4>Calls at Positions</h4>
        <table>
          <thead>
          <tr>
            <th>Position</th>
            <th>RSID</th>
            <th>Call</th>
            <th>Reference</th>
            <th>Related Alleles</th>
          </tr>
          </thead>
          <tbody>
          
            <tr>
              <td id="15879621">15879621</td>
              <td id="rs2108622">rs2108622</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *3 
              </td>
            </tr>
          
            <tr>
              <td id="15897578">15897578</td>
              <td id="rs3093105">rs3093105</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *2 
              </td>
            </tr>
          
          </tbody>
        </table>
      

      
    </section>
  
    <section class="gene">
      <h3 id="DPYD">DPYD allele match data</h3>

      <h4>Genotype matched</h4>
      <ul>
        
          <li>No CPIC decreased or no function variant with strong or moderate evidence found</li>
        
      </ul>

      <h4>Phasing status</h4><div>Phased</div>

      

      

      

      

      

      
        <h4>Calls at Positions</h4>
        <table>
          <thead>
          <tr>
            <th>Position</th>
            <th>RSID</th>
            <th>Call</th>
            <th>Reference</th>
            <th>Related Alleles</th>
          </tr>
          </thead>
          <tbody>
          
            <tr>
              <td id="97079071">97079071</td>
              <td id="rs1801268">rs1801268</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                c.2983G&gt;T 
              </td>
            </tr>
          
            <tr>
              <td id="97082391">97082391</td>
              <td id="rs67376798">rs67376798</td>
              
              
                <td class="">T|T</td>
              
              <td>
                T
              </td>
              <td>
                c.2846A&gt;T 
              </td>
            </tr>
          
            <tr>
              <td id="97450058">97450058</td>
              <td id="rs3918290">rs3918290</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                c.1905+1G&gt;A 
              </td>
            </tr>
          
            <tr>
              <td id="97450066">97450066</td>
              <td id="rs72549303">rs72549303</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                c.1898delC 
              </td>
            </tr>
          
            <tr>
              <td id="97515787">97515787</td>
              <td id="rs55886062">rs55886062</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                c.1679T&gt;G 
              </td>
            </tr>
          
            <tr>
              <td id="97573943">97573943</td>
              <td id="rs78060119">rs78060119</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                c.1156G&gt;T 
              </td>
            </tr>
          
            <tr>
              <td id="97579893">97579893</td>
              <td id="rs75017182">rs75017182</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                c.1129-5923C&gt;G 
              </td>
            </tr>
          
            <tr>
              <td id="97691776">97691776</td>
              <td id="rs1801266">rs1801266</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                c.703C&gt;T 
              </td>
            </tr>
          
            <tr>
              <td id="97699474">97699474</td>
              <td id="rs115232898">rs115232898</td>
              
              
                <td class="">T|T</td>
              
              <td>
                T
              </td>
              <td>
                c.557A&gt;G 
              </td>
            </tr>
          
            <tr>
              <td id="97740415">97740415</td>
              <td id="rs72549309">rs72549309</td>
              
              
                <td class="">AGTA|AGTA</td>
              
              <td>
                AGTA
              </td>
              <td>
                c.295_298delTCAT 
              </td>
            </tr>
          
          </tbody>
        </table>
      

      
        <h4>Other Positions of Interest</h4>
        
          <div class="alert alert-warning">These variants are included in the CPIC supplementary material for DPYD. Variants with 'In vitro data only and/or limited clinical/ex vivo data' evidence level are not specifically included in the CPIC recommendations. The table also lists normal function variants with different evidence levels based on the guideline information. For further details follow the link to the CPIC page in the fluorouracil or capecitabine drug section.</div>
        
        <table>
          <thead>
          <tr>
            <th>Position</th>
            <th>RSID</th>
            <th>Call</th>
          </tr>
          </thead>
          <tbody>
          
            <tr>
              <td id="97078987">97078987</td>
              <td id="rs114096998">rs114096998</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97078993">97078993</td>
              <td id="rs148799944">rs148799944</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97079005">97079005</td>
              <td id="rs140114515">rs140114515</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97079076">97079076</td>
              <td id="rs139459586">rs139459586</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97079077">97079077</td>
              <td id="rs202144771">rs202144771</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97079121">97079121</td>
              <td id="rs72547601">rs72547601</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97079133">97079133</td>
              <td id="rs72547602">rs72547602</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97079139">97079139</td>
              <td id="rs145529148">rs145529148</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97082365">97082365</td>
              <td id="rs141044036">rs141044036</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97098598">97098598</td>
              <td id="rs1801267">rs1801267</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97098599">97098599</td>
              <td id="rs147545709">rs147545709</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97098616">97098616</td>
              <td id="rs55674432">rs55674432</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97098632">97098632</td>
              <td id="rs201035051">rs201035051</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97193109">97193109</td>
              <td id="rs60139309">rs60139309</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97193209">97193209</td>
              <td id="rs200687447">rs200687447</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97234958">97234958</td>
              <td id="rs199634007">rs199634007</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97234991">97234991</td>
              <td id="rs56005131">rs56005131</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97235033">97235033</td>
              <td id="rs12137711">rs12137711</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97305279">97305279</td>
              <td id="rs112766203">rs112766203</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97305363">97305363</td>
              <td id="rs60511679">rs60511679</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97305364">97305364</td>
              <td id="rs1801160">rs1801160</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97305372">97305372</td>
              <td id="rs146529561">rs146529561</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97306195">97306195</td>
              <td id="rs145548112">rs145548112</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97373598">97373598</td>
              <td id="rs137999090">rs137999090</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97373629">97373629</td>
              <td id="rs138545885">rs138545885</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97382461">97382461</td>
              <td id="rs55971861">rs55971861</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97450059">97450059</td>
              <td id="rs3918289">rs3918289</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97450068">97450068</td>
              <td id="rs17376848">rs17376848</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97450168">97450168</td>
              <td id="rs147601618">rs147601618</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97450187">97450187</td>
              <td id="rs145773863">rs145773863</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97450189">97450189</td>
              <td id="rs138616379">rs138616379</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97450190">97450190</td>
              <td id="rs59086055">rs59086055</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97515686">97515686</td>
              <td id="rs2811178">rs2811178</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97515687">97515687</td>
              <td id="rs2786783">rs2786783</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97515784">97515784</td>
              <td id="rs201615754">rs201615754</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97515839">97515839</td>
              <td id="rs1801159">rs1801159</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97515851">97515851</td>
              <td id="rs142619737">rs142619737</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97515865">97515865</td>
              <td id="rs1801158">rs1801158</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97515889">97515889</td>
              <td id="rs190951787">rs190951787</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97515923">97515923</td>
              <td id="rs148994843">rs148994843</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97549565">97549565</td>
              <td id="rs138391898">rs138391898</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97549600">97549600</td>
              <td id="rs111858276">rs111858276</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97549609">97549609</td>
              <td id="rs72549304">rs72549304</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97549681">97549681</td>
              <td id="rs199549923">rs199549923</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97549713">97549713</td>
              <td id="rs57918000">rs57918000</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97549726">97549726</td>
              <td id="rs144395748">rs144395748</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97549735">97549735</td>
              <td id="rs72975710">rs72975710</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97549850">97549850</td>
              <td id="rs61789183">rs61789183</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97573785">97573785</td>
              <td id="rs186169810">rs186169810</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97573805">97573805</td>
              <td id="rs142512579">rs142512579</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97573821">97573821</td>
              <td id="rs764666241">rs764666241</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97573839">97573839</td>
              <td id="rs200064537">rs200064537</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97573881">97573881</td>
              <td id="rs61622928">rs61622928</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97573918">97573918</td>
              <td id="rs143815742">rs143815742</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97573919">97573919</td>
              <td id="rs140602333">rs140602333</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97573985">97573985</td>
              <td id="rs56293913">rs56293913</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97573998">97573998</td>
              <td id="rs368600943">rs368600943</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97593238">97593238</td>
              <td id="rs72549305">rs72549305</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97593289">97593289</td>
              <td id="rs143154602">rs143154602</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97593322">97593322</td>
              <td id="rs183385770">rs183385770</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97593343">97593343</td>
              <td id="rs72549306">rs72549306</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97593379">97593379</td>
              <td id="rs201018345">rs201018345</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97594925">97594925</td>
              <td id="rs2811202">rs2811202</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97595083">97595083</td>
              <td id="rs145112791">rs145112791</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97595088">97595088</td>
              <td id="rs150437414">rs150437414</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97595149">97595149</td>
              <td id="rs146356975">rs146356975</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97679004">97679004</td>
              <td id="rs138924556">rs138924556</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97679054">97679054</td>
              <td id="rs112550271">rs112550271</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97679170">97679170</td>
              <td id="rs45589337">rs45589337</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97679300">97679300</td>
              <td id="rs3790387">rs3790387</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97691806">97691806</td>
              <td id="rs74774246">rs74774246</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97699212">97699212</td>
              <td id="rs6668296">rs6668296</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97699399">97699399</td>
              <td id="rs72549307">rs72549307</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97699430">97699430</td>
              <td id="rs72549308">rs72549308</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97699506">97699506</td>
              <td id="rs6670886">rs6670886</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97699533">97699533</td>
              <td id="rs139834141">rs139834141</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97699535">97699535</td>
              <td id="rs2297595">rs2297595</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97721542">97721542</td>
              <td id="rs200562975">rs200562975</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97721650">97721650</td>
              <td id="rs141462178">rs141462178</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97740400">97740400</td>
              <td id="rs150385342">rs150385342</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97740602">97740602</td>
              <td id="rs41309171">rs41309171</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97828265">97828265</td>
              <td id="rs115632870">rs115632870</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97883329">97883329</td>
              <td id="rs1801265">rs1801265</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97883352">97883352</td>
              <td id="rs80081766">rs80081766</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97883353">97883353</td>
              <td id="rs72549310">rs72549310</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
            <tr>
              <td id="97883368">97883368</td>
              <td id="rs150036960">rs150036960</td>
              
                <td class="missingVariant"><em>missing</em></td>
              
              
            </tr>
          
          </tbody>
        </table>
      
    </section>
  
    <section class="gene">
      <h3 id="IFNL3">IFNL3 allele match data</h3>

      <h4>Genotype matched</h4>
      <ul>
        
          <li>rs12979860C/rs12979860C</li>
        
      </ul>

      <h4>Phasing status</h4><div>Phased</div>

      

      

      

      

      

      
        <h4>Calls at Positions</h4>
        <table>
          <thead>
          <tr>
            <th>Position</th>
            <th>RSID</th>
            <th>Call</th>
            <th>Reference</th>
            <th>Related Alleles</th>
          </tr>
          </thead>
          <tbody>
          
            <tr>
              <td id="39248147">39248147</td>
              <td id="rs12979860">rs12979860</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                rs12979860T 
              </td>
            </tr>
          
          </tbody>
        </table>
      

      
    </section>
  
    <section class="gene">
      <h3 id="SLCO1B1">SLCO1B1 allele match data</h3>

      <h4>Genotype matched</h4>
      <ul>
        
          <li>*1A/*1A</li>
        
          <li>rs4149056T/rs4149056T</li>
        
      </ul>

      <h4>Phasing status</h4><div>Phased</div>

      

      

      

      

      

      
        <h4>Calls at Positions</h4>
        <table>
          <thead>
          <tr>
            <th>Position</th>
            <th>RSID</th>
            <th>Call</th>
            <th>Reference</th>
            <th>Related Alleles</th>
          </tr>
          </thead>
          <tbody>
          
            <tr>
              <td id="21130388">21130388</td>
              <td id="rs4149015">rs4149015</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *17 *21 
              </td>
            </tr>
          
            <tr>
              <td id="21172734">21172734</td>
              <td id="rs139257324">rs139257324</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *33 
              </td>
            </tr>
          
            <tr>
              <td id="21172776">21172776</td>
              <td id="rs373327528">rs373327528</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *23 
              </td>
            </tr>
          
            <tr>
              <td id="21172782">21172782</td>
              <td id="rs56101265">rs56101265</td>
              
              
                <td class="">T|T</td>
              
              <td>
                T
              </td>
              <td>
                *2 *12 
              </td>
            </tr>
          
            <tr>
              <td id="21174595">21174595</td>
              <td id="rs56061388">rs56061388</td>
              
              
                <td class="">T|T</td>
              
              <td>
                T
              </td>
              <td>
                *3 *13 
              </td>
            </tr>
          
            <tr>
              <td id="21176804">21176804</td>
              <td id="rs2306283">rs2306283</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *1B *14 *15 *17 *18 *20 *21 *24 *25 *27 *28 *29 *30 *31 *32 *33 *35 
              </td>
            </tr>
          
            <tr>
              <td id="21176827">21176827</td>
              <td id="rs11045818">rs11045818</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *18 
              </td>
            </tr>
          
            <tr>
              <td id="21176868">21176868</td>
              <td id="rs2306282">rs2306282</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *16 
              </td>
            </tr>
          
            <tr>
              <td id="21176879">21176879</td>
              <td id="rs11045819">rs11045819</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *4 *14 *18 *25 *32 
              </td>
            </tr>
          
            <tr>
              <td id="21176883">21176883</td>
              <td id="rs72559745">rs72559745</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *3 *13 
              </td>
            </tr>
          
            <tr>
              <td id="21178615">21178615</td>
              <td id="rs4149056">rs4149056</td>
              
              
                <td class="">T|T</td>
              
              <td>
                T
              </td>
              <td>
                *5 *15 *17 
              </td>
            </tr>
          
            <tr>
              <td id="21178665">21178665</td>
              <td id="rs4149057">rs4149057</td>
              
              
                <td class="">T|T</td>
              
              <td>
                T
              </td>
              <td>
                *18 *19 
              </td>
            </tr>
          
            <tr>
              <td id="21178672">21178672</td>
              <td id="rs72559746">rs72559746</td>
              
              
                <td class="">T|T</td>
              
              <td>
                T
              </td>
              <td>
                *18 
              </td>
            </tr>
          
            <tr>
              <td id="21178691">21178691</td>
              <td id="rs2291075">rs2291075</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *20 *21 
              </td>
            </tr>
          
            <tr>
              <td id="21178957">21178957</td>
              <td id="rs79135870">rs79135870</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *30 
              </td>
            </tr>
          
            <tr>
              <td id="21196951">21196951</td>
              <td id="rs11045852">rs11045852</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *24 *25 *28 *32 *33 
              </td>
            </tr>
          
            <tr>
              <td id="21196976">21196976</td>
              <td id="rs11045853">rs11045853</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *25 *28 *33 
              </td>
            </tr>
          
            <tr>
              <td id="21200595">21200595</td>
              <td id="rs55901008">rs55901008</td>
              
              
                <td class="">T|T</td>
              
              <td>
                T
              </td>
              <td>
                *6 
              </td>
            </tr>
          
            <tr>
              <td id="21202553">21202553</td>
              <td id=""></td>
              
              
                <td class="">T|T</td>
              
              <td>
                T
              </td>
              <td>
                *36 
              </td>
            </tr>
          
            <tr>
              <td id="21202555">21202555</td>
              <td id="rs59113707">rs59113707</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *27 
              </td>
            </tr>
          
            <tr>
              <td id="21202649">21202649</td>
              <td id="rs56387224">rs56387224</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *7 
              </td>
            </tr>
          
            <tr>
              <td id="21202664">21202664</td>
              <td id="rs142965323">rs142965323</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *26 
              </td>
            </tr>
          
            <tr>
              <td id="21205921">21205921</td>
              <td id="rs72559748">rs72559748</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *8 
              </td>
            </tr>
          
            <tr>
              <td id="21205999">21205999</td>
              <td id="rs59502379">rs59502379</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *9 *31 
              </td>
            </tr>
          
            <tr>
              <td id="21239042">21239042</td>
              <td id="rs34671512">rs34671512</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *19 *20 *22 *35 
              </td>
            </tr>
          
            <tr>
              <td id="21239077">21239077</td>
              <td id="rs56199088">rs56199088</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *10 *12 
              </td>
            </tr>
          
            <tr>
              <td id="21239113">21239113</td>
              <td id="rs55737008">rs55737008</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *11 *13 
              </td>
            </tr>
          
            <tr>
              <td id="21239145">21239145</td>
              <td id="rs200995543">rs200995543</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *34 
              </td>
            </tr>
          
            <tr>
              <td id="21239158">21239158</td>
              <td id="rs140790673">rs140790673</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *29 
              </td>
            </tr>
          
          </tbody>
        </table>
      

      
    </section>
  
    <section class="gene">
      <h3 id="TPMT">TPMT allele match data</h3>

      <h4>Genotype matched</h4>
      <ul>
        
          <li>*1/*1</li>
        
      </ul>

      <h4>Phasing status</h4><div>Phased</div>

      

      

      

      

      

      
        <h4>Calls at Positions</h4>
        <table>
          <thead>
          <tr>
            <th>Position</th>
            <th>RSID</th>
            <th>Call</th>
            <th>Reference</th>
            <th>Related Alleles</th>
          </tr>
          </thead>
          <tbody>
          
            <tr>
              <td id="18130687">18130687</td>
              <td id="rs1142345">rs1142345</td>
              
              
                <td class="">T|T</td>
              
              <td>
                T
              </td>
              <td>
                *3A *3C 
              </td>
            </tr>
          
            <tr>
              <td id="18130694">18130694</td>
              <td id="rs150900439">rs150900439</td>
              
              
                <td class="">T|T</td>
              
              <td>
                T
              </td>
              <td>
                *20 
              </td>
            </tr>
          
            <tr>
              <td id="18130725">18130725</td>
              <td id="rs72552736">rs72552736</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *7 
              </td>
            </tr>
          
            <tr>
              <td id="18130762">18130762</td>
              <td id="rs56161402">rs56161402</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *8 
              </td>
            </tr>
          
            <tr>
              <td id="18130772">18130772</td>
              <td id="rs377085266">rs377085266</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *25 
              </td>
            </tr>
          
            <tr>
              <td id="18130781">18130781</td>
              <td id="rs1800584">rs1800584</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *4 
              </td>
            </tr>
          
            <tr>
              <td id="18132136">18132136</td>
              <td id="rs72556347">rs72556347</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *26 
              </td>
            </tr>
          
            <tr>
              <td id="18132147">18132147</td>
              <td id="rs79901429">rs79901429</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *31 
              </td>
            </tr>
          
            <tr>
              <td id="18133845">18133845</td>
              <td id="rs75543815">rs75543815</td>
              
              
                <td class="">T|T</td>
              
              <td>
                T
              </td>
              <td>
                *6 
              </td>
            </tr>
          
            <tr>
              <td id="18133847">18133847</td>
              <td id="rs6921269">rs6921269</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *24 
              </td>
            </tr>
          
            <tr>
              <td id="18133884">18133884</td>
              <td id="rs74423290">rs74423290</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *23 
              </td>
            </tr>
          
            <tr>
              <td id="18133890">18133890</td>
              <td id="rs9333570">rs9333570</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *15 
              </td>
            </tr>
          
            <tr>
              <td id="18138969">18138969</td>
              <td id="rs144041067">rs144041067</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *16 *22 
              </td>
            </tr>
          
            <tr>
              <td id="18138997">18138997</td>
              <td id="rs1800460">rs1800460</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *3A *3B 
              </td>
            </tr>
          
            <tr>
              <td id="18139027">18139027</td>
              <td id="rs72552737">rs72552737</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *10 
              </td>
            </tr>
          
            <tr>
              <td id="18139689">18139689</td>
              <td id="rs72552738">rs72552738</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *11 
              </td>
            </tr>
          
            <tr>
              <td id="18139710">18139710</td>
              <td id="rs200220210">rs200220210</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *12 
              </td>
            </tr>
          
            <tr>
              <td id="18143597">18143597</td>
              <td id=""></td>
              
              
                <td class="">T|T</td>
              
              <td>
                T
              </td>
              <td>
                *19 
              </td>
            </tr>
          
            <tr>
              <td id="18143606">18143606</td>
              <td id="rs151149760">rs151149760</td>
              
              
                <td class="">T|T</td>
              
              <td>
                T
              </td>
              <td>
                *9 
              </td>
            </tr>
          
            <tr>
              <td id="18143613">18143613</td>
              <td id=""></td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *28 
              </td>
            </tr>
          
            <tr>
              <td id="18143643">18143643</td>
              <td id=""></td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *27 
              </td>
            </tr>
          
            <tr>
              <td id="18143724">18143724</td>
              <td id="rs1800462">rs1800462</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *2 
              </td>
            </tr>
          
            <tr>
              <td id="18147845">18147845</td>
              <td id=""></td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *18 
              </td>
            </tr>
          
            <tr>
              <td id="18147851">18147851</td>
              <td id="rs200591577">rs200591577</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *21 
              </td>
            </tr>
          
            <tr>
              <td id="18147910">18147910</td>
              <td id="rs72552740">rs72552740</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *5 
              </td>
            </tr>
          
            <tr>
              <td id="18149004">18149004</td>
              <td id=""></td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *17 
              </td>
            </tr>
          
            <tr>
              <td id="18149022">18149022</td>
              <td id=""></td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *30 
              </td>
            </tr>
          
            <tr>
              <td id="18149045">18149045</td>
              <td id="rs72552742">rs72552742</td>
              
              
                <td class="">T|T</td>
              
              <td>
                T
              </td>
              <td>
                *13 
              </td>
            </tr>
          
            <tr>
              <td id="18149126">18149126</td>
              <td id="rs267607275">rs267607275</td>
              
              
                <td class="">A|A</td>
              
              <td>
                A
              </td>
              <td>
                *29 
              </td>
            </tr>
          
            <tr>
              <td id="18149127">18149127</td>
              <td id="rs9333569">rs9333569</td>
              
              
                <td class="">T|T</td>
              
              <td>
                T
              </td>
              <td>
                *14 
              </td>
            </tr>
          
          </tbody>
        </table>
      

      
        <h4>Other Positions of Interest</h4>
        
          <div class="alert alert-warning">The following position is included in the CPIC TPMT allele defintions but not in the recommendation.</div>
        
        <table>
          <thead>
          <tr>
            <th>Position</th>
            <th>RSID</th>
            <th>Call</th>
          </tr>
          </thead>
          <tbody>
          
            <tr>
              <td id="18138983">18138983</td>
              <td id="rs2842934">rs2842934</td>
              
              
                <td class="">G|G</td>
              
            </tr>
          
          </tbody>
        </table>
      
    </section>
  
    <section class="gene">
      <h3 id="UGT1A1">UGT1A1 allele match data</h3>

      <h4>Genotype matched</h4>
      <ul>
        
          <li>*1/*1</li>
        
      </ul>

      <h4>Phasing status</h4><div>Phased</div>

      

      

      

      

      
        <div class="alert alert-warning">UGT1A1*80 (rs887829) is in very high linkage disequilibrium with *28 and *37 (TA repeat variation in the UGT1A1 promoter). In case *80 (rs887829) is detected and input at position 233760233 (*28/*37) is MISSING from the VCF, the allele options are presented as *80+*28 and *80+*37 based on a partial match for *80, and *80 is used to infer metabolizer status.<br><br>In case *80 is detected with position 233760233 (*28/*37) detected as reference (shown as reference in row 233760233 in the table Calls at Position), not enough clinical data exists to predict metabolizer status with certainty and provide recommendations. Therefore, the presence of *80 (without the *28 or *37 variant) is not considered in the determination of the UGT1A1 genotype by itself. </div>
      

      
        <h4>Calls at Positions</h4>
        <table>
          <thead>
          <tr>
            <th>Position</th>
            <th>RSID</th>
            <th>Call</th>
            <th>Reference</th>
            <th>Related Alleles</th>
          </tr>
          </thead>
          <tbody>
          
            <tr>
              <td id="233757013">233757013</td>
              <td id="rs4124874">rs4124874</td>
              
              
                <td class="">T|T</td>
              
              <td>
                T
              </td>
              <td>
                *60 
              </td>
            </tr>
          
            <tr>
              <td id="233759924">233759924</td>
              <td id="rs887829">rs887829</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *80+*28 *80+*37 
              </td>
            </tr>
          
            <tr>
              <td id="233760233">233760233</td>
              <td id=""></td>
              
              
                <td class="">CAT|CAT</td>
              
              <td>
                CAT
              </td>
              <td>
                *28 *36 *37 *80+*28 *80+*37 
              </td>
            </tr>
          
            <tr>
              <td id="233760498">233760498</td>
              <td id="rs4148323">rs4148323</td>
              
              
                <td class="">G|G</td>
              
              <td>
                G
              </td>
              <td>
                *6 
              </td>
            </tr>
          
            <tr>
              <td id="233760973">233760973</td>
              <td id="rs35350960">rs35350960</td>
              
              
                <td class="">C|C</td>
              
              <td>
                C
              </td>
              <td>
                *27 
              </td>
            </tr>
          
          </tbody>
        </table>
      

      
    </section>
  
    <section class="gene">
      <h3 id="VKORC1">VKORC1 allele match data</h3>

      <h4>Genotype matched</h4>
      <ul>
        
          <li>-1639A/-1639A</li>
        
      </ul>

      <h4>Phasing status</h4><div>Phased</div>

      

      

      

      

      

      
        <h4>Calls at Positions</h4>
        <table>
          <thead>
          <tr>
            <th>Position</th>
            <th>RSID</th>
            <th>Call</th>
            <th>Reference</th>
            <th>Related Alleles</th>
          </tr>
          </thead>
          <tbody>
          
            <tr>
              <td id="31096368">31096368</td>
              <td id="rs9923231">rs9923231</td>
              
              
                <td class="nonwild">T|T</td>
              
              <td>
                C
              </td>
              <td>
                -1639A 
              </td>
            </tr>
          
          </tbody>
        </table>
      

      
    </section>
  
</section>

<section id="disclaimer">
  <h2>Disclaimers and Other Information</h2>

  <p id="liability">Liability:  PhamCAT assumes no responsibility for any injury to person or damage to persons or property arising out of, or related to any use of PharmCAT, or for any errors or omissions. The user recognizes that PharmCAT is a research tool and that they are using PharmCAT at their own risk.</p>

  <h3>A. Allele and Genotype Determination</h3>
  <ol type="i">
    <li>PharmCAT uses <a href="https://www.pharmgkb.org/page/pgxGeneRef">gene allele definitions from CPIC</a>, with exceptions as noted in <a href="https://docs.google.com/document/d/1X9Kl5gKLGvQfMY3nYbto0D3R4ZoBrR6mIYQiqMhFSbY/edit?usp=sharing">Gene Definition Exceptions document</a>.  For allele definitions and the positions used in PharmCAT, see the <a href="https://github.com/PharmGKB/PharmCAT/releases">gene definition tables</a>.</li>
    <li>PharmCAT results are dependent on the supplied vcf calls for the queried positions (for technical information about PharmCAT input formatting and requirements, please go to <a href="http://pharmcat.org/">pharmcat.org</a>). PharmCAT does not assume any reference calls for positions missing from the submitted vcf; all missing queried positions are not considered in the allele determination process. See the <a href="https://github.com/PharmGKB/PharmCAT/releases">gene definition tables</a> for more information about what positions are queried in the vcf.  Missing positions might alter the assigned genotype, subsequent phenotype prediction and CPIC recommendation. If the supplied vcf is missing positions, those positions will be noted in Section 3: Allele Calls for each gene of this report.  For the most reliable allele determination, reference calls as well as variant calls in the vcf for every queried position must be provided by the user.</li>
    <li>For cytochrome P450 genes, TPMT, DPYD, and SLCO1B1, the *1 (or reference in case of DPYD) allele is defined by the absence of variation specified in the gene definition tables. This allele cannot be identified by variants; rather, *1 is assigned by default when no variation for the queried positions is reported in the submitted vcf. It is always possible un-interrogated variation can occur which could potentially affect allele function, but because it is undetected, the assignment would be defaulted to a *1 allele and normal function.</li>
    <li>For all genes, variation reported in the vcf but NOT included in the gene definition table will not be considered during allele assignment.  There is a possibility that any such variation results in a reduced or no activity allele which could lead to inaccurate phenotype and CPIC recommendation, similar to the situation in point iii, above.</li>
    <li>PharmCAT matches variants to genotypes using unphased data (unless phased data is provided in the vcf and noted as such, see <a href="http://pharmcat.org/">pharmcat.org</a> for details). The assumption is that defined alleles exist in trans configuration, i.e. on opposite chromosomes, with exceptions noted in Section 3: Allele Calls under “Gene-specific warnings.”  However, in cases where an allele is defined by a combination of two or more variants, where each variant alone also defines an allele, the match is based on the longer allele (except for UGT1A1). For example, CYP2C19*4A is defined one SNP, *17 is defined by another SNP, and *4B is defined by the combination of those two SNPs.  In the case of unphased data that is heterozygous for both SNPs, the *1/*4B genotype is returned though the possibility of *4A/*17 cannot be ruled out.</li>
    <li>Nucleotide base calls are displayed on the positive chromosomal strand regardless of the gene strand; further information is provided under Gene-specific warnings in Section 3: Allele Calls.</li>
  </ol>

  <h3>B. CPIC Allele Function, Phenotype and Recommendation</h3>
  <ol type="i">
    <li>
      Allele functionality and phenotype terms are based on the <a href="https://cpicpgx.org/wp-content/uploads/2016/01/CPIC_term_standardization_project_final_terms.pdf">CPIC Term Standardization Project</a> [PMID: 27441996].  Please see this reference for details but note the following changes from original CPIC guidelines based on this project:
      <ol type="a">
        <li>This terminology replaces the term ‘extensive’ metabolizer with ‘normal’ metabolizer for drug metabolizing enzymes such as CYPs, DPYD, TPMT, UGT1A1. Guidelines published prior to this recommendation used the term ‘extensive’ metabolizer whereas the PharmCAT report uses ‘normal’.</li>
        <li>The terminology introduces the use of the term ‘rapid’ metabolizer for CYP2C19*1/*17 to distinguish between *1/*17  and *17/*17 (‘ultrarapid’ metabolizer). CYP2C19 *1/*17 was grouped as ‘ultrarapid’ metabolizer in prior guidelines. PharmCAT uses the ‘rapid’ metabolizer group.</li>
        <li>PharmCAT uses allele functions from <a href="https://www.pharmgkb.org/page/pgxGeneRef">gene information tables</a>, including alleles with ‘possible’ or ‘likely’ added to the function term.</li>
      </ol>
    </li>
    <li>PharmCAT uses metabolizer phenotypes from <a href="https://www.pharmgkb.org/page/pgxGeneRef">gene information tables</a>. ‘Likely’ or ‘possible’ metabolizer phenotypes are originally based on supplemental materials for respective guidelines and are listed in the gene “Diplotype-Phenotype Table.”</li>
    <li>PharmCAT uses recommendation wording as provided in the CPIC guideline. CPIC typically provides the same recommendations for ‘likely’ or ‘possible’ metabolizer phenotypes in supplemental and <a href="https://www.pharmgkb.org/page/pgxGeneRef">gene information tables</a> as those without the ‘likely’ or ‘possible’ labels, but do not provide a strength of therapeutic recommendation.</li>
  </ol>

  <h3>C. CYP2D6 Allele Determination and Metabolizer Status</h3>
  <ol type="i">
    <li>CYP2D6 genotypes are based on <a href="http://www.childrensmercy.org/Health_Care_Professionals/Research/Pediatric_Genomic_Medicine/Software_Tools/">Astrolabe</a> calls. For specific disclaimers and limitations, see the <a href="http://www.childrensmercy.org/Health_Care_Professionals/Research/Pediatric_Genomic_Medicine/Software_Tools/">Astrolabe</a> documentation and specifications made available with the product.</li>
    <li>Metabolizer Status: CPIC classifies genotypes with a gene activity score of 1.0 as normal metabolizers; however, other guidelines or reference laboratories may classify the same genotypes as intermediate metabolizers.</li>
  </ol>

  <h3>D. Prescribing Change Designations</h3>
  <ol type="i">
    <li>
      The drugs in Section 1: Genotype summary table are colored to indicate whether CPIC recommends a prescribing change based on the given genotype; highlighting is not based on CPIC classification of recommendation.
      <ol type="a">
        <li><span class="rxChange"><i class="fa fa-times"></i> Red</span> indicates a prescribing change is recommended for the given genotype. That is, the recommendation is different than ‘use label recommendation’ or ‘use recommended starting dose’, except for ivacaftor.</li>
        <li><span class="rxPossibly"><i class="fa fa-warning"></i> Orange</span> indicates possible prescribing changes depending on additional information, e.g. pediatrics vs. adult, or the specific number of CYP2D6 normal alleles present (copy number).</li>
        <li><span class="normal"><i class="fa fa-circle"></i> Green</span> indicates that there is no CPIC recommended prescribing change for the given genotype, except for ivacaftor.</li>
        <li><span class="highlight"><i class="fa fa-square"></i> Blue</span> indicates the specific guideline must be consulted because a CPIC recommended action cannot be provided based solely on genotype (eg. warfarin and ribavirin/peginterferon).</li>
      </ol>
    </li>
    <li>When multiple genotypes are possible for a gene, the drug is highlighted according to the highest level of prescribing change.</li>
  </ol>

  <h3>E. PharmCAT Exceptions to the CPIC Guideline Gene List</h3>
  <ol type="i">
    <li>HLA-B and G6PD are currently not included in PharmCAT. Therefore, no CPIC guideline recommendations are included for these genes.</li>
    <li>Further genes will be incorporated into PharmCAT as the tool is developed.</li>
  </ol>

  <h3>F. PharmCAT Updates</h3>
  <ol type="i">
    <li>PharmCAT monitors publication of new CPIC guidelines and guideline updates. New publication content will be included into PharmCAT within one month of CPIC publication.</li>
    <li>Updates to the gene definition tables may occur, the latest version can be found alongside <a href="https://github.com/PharmGKB/PharmCAT/releases">the software releases</a>.</li>
    <li>Updates to PharmCAT may occur, for the latest version go to the <a href="https://github.com/PharmGKB/PharmCAT/releases">PharmCAT release page</a>.</li>
  </ol>

  <h3>G. CPIC Guideline Disclaimers and Caveats</h3>
  <ol type="i">
    <li>
      A version of the following quoted disclaimer is part of each CPIC guideline and applies to the CPIC recommendations as used in PharmCAT. For the full description of potential benefits and risks, additional considerations (general and specific to gene-drug pairs), limitations, information about respective gene nomenclature systems, potential drug-drug interactions and clinical factors to consider, please see individual CPIC guidelines (<a href="https://cpicpgx.org">cpicpgx.org</a>).
      <ol type="a">
        <li>“CPIC guidelines reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision making and to identify questions for further research. New evidence may have emerged since the time a guideline was submitted for publication. Guidelines are limited in scope and are not applicable to interventions or diseases not specifically identified. Guidelines do not account for all individual variations among patients and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guidelines is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. CPIC assumes no responsibility for any injury to persons or damage to persons or property arising out of or related to any use of CPIC’s guidelines, or for any errors or omissions.”  (PMID: <a href="https://www.ncbi.nlm.nih.gov/pubmed/27997040">27997040</a>)</li>
        <li>“Caveats: appropriate use and/or potential misuse of genetic tests. The application of genotype-based dosing is most appropriate when initiating therapy with a tricyclic. Obtaining a pharmacogenetic test after months of drug therapy may be less helpful in some instances, as the drug dose may have already been adjusted based on plasma concentrations, response, or side effects. Similar to all diagnostic tests, genetic tests are one of several pieces of clinical information that should be considered before initiating drug therapy.” (PMID: <a href="https://www.ncbi.nlm.nih.gov/pubmed/27997040">27997040</a>)</li>
      </ol>
    </li>
    <li>CPIC guidelines reflect the alleles/genotypes known and considered by the guideline authors for inclusion by the time of publication, however they may be updated online at <a href="https://cpicpgx.org">cpicpgx.org</a> in between publications. Additional alleles and/or more extensive allele definitions might exist by the representative gene nomenclatures for various genes.</li>
    <li>CPIC is a registered service mark of the U.S. Department of Health & Human Services (HHS).</li>
  </ol>

  <h3>H. PharmGKB Disclaimers and Caveats</h3>
  <ol type="i">
    <li>PharmGKB is a registered service mark of the U.S. Department of Health & Human Services (HHS).</li>
  </ol>
</section>


</body>
</html>
